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1 Abstract 
THORACENTESIS IN CARDIAC SURGERY PATIENTS WITH NON-SPECIFIC PLEURAL 
EFFUSION:  A CASE-CONTROL STUDY 
David R. Kull, Barbara Stahl1, Gaetane C. Michaud3, Christina Carbone3, Kelsey Johnson3, Eileen Taylor2, 
Vladimir Shumaster2, Ann Roselle2, Jonathan Puchalski3, Rowena Saga-Abrina2, and Umer M. Darr2 
(Sponsored by Frank C. Detterbeck1). 
Department of Surgery, Sections of Cardiac1 and Thoracic Surgery2; and Department of Medicine, Section 
of Pulmonary and Critical Care Medicine3, Yale University, School of Medicine, New Haven, CT. 
Non-specific pleural effusion is common in patients after cardiac surgery. Thoracentesis for non-
specific pleural effusion is being used more frequently with informal observations of improved dyspnea, 
shorter length of inpatient stay (LOS), reduced need for escalation of care, and less postoperative atrial 
fibrillation (AF).  Our hypothesis is that the majority of cardiac surgery patients who undergo thoracentesis 
for non-specific pleural effusion have improvements in dyspnea, reduced days in AF, and reduced 
escalation of care compared to similar patients who do not have procedural intervention. 
Our study population includes patients with evidence of pleural effusion on chest x-ray during a 
period postoperative day (POD) 3 – 7, after cardiac surgery performed by a single surgeon at Yale - New 
Haven Hospital, between Jan. 2013 and Dec. 2014.  We have conducted a retrospective Case – Control 
Study (n = 30, 15/15).  Cases are defined as having thoracentesis POD3 – POD7 and are matched by age 
and cardiac operation to Controls.  We have recorded the frequency of improved dyspnea, as defined by ≥2 
LPM reduction of daily peak O2 supplementation, after thoracentesis for Cases and compared this to the 
same period for matched Controls.  Postoperative LOS, incidence of AF, and requirement for escalation of 
care are recorded and compared between Cases and Controls.   
Dyspnea improved for 73% of Cases but this was not significantly different compared to Controls 
during matched periods (11 vs. 7 patients, OR = 3.1, p = 0.14).  Length of stay was not different between 
Cases and Controls (6.7 vs. 5.8 days, p = 0.84) and there was no escalation of care required in either group 
(95% CI, 0.00 – 0.14).  There was no difference in the odds of postoperative AF between Cases and 
Controls (OR = 0.22, p = 0.13).  Patients who had thoracentesis performed before POD5 significantly lower 
incidence of postoperative AF (0 vs. 6 patients, p = 0.01).  
We have concluded that the majority of patients have improvement in dyspnea after thoracentesis for 
non-specific pleural effusion after cardiac surgery.  We observed that this improvement is not significantly 
different than that experienced by similar control patients.  Thoracentesis did not decrease length of stay.  
Patients might experience fewer days in AF with thoracentesis when performed before POD5.  Preoperative 
risk factors for postoperative AF were not evaluated, could have introduced selection bias for Cases, and 
therefore, limits this result. 
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3 Introduction 
3.1 Non-Specific Pleural Effusion in Cardiac Surgery Patients 
Indications for Cardiac Surgery include some of the most common diseases in the United States: 
including coronary artery disease, valvular heart disease, and other structural heart disease.  Coronary 
Artery Bypass Graft (CABG) for patients with coronary artery disease is one of the most common cardiac 
surgical procedures and accounts for approximately 400,000 hospital discharges per year in the United 
States[1].  Aortic Valve Repair (AVR) accounts for an additional 200,000 discharges in the United States 
annually[2].  Limiting postoperative conditions that can prolong recovery after cardiac surgery has 
importance in patient health and resource utilization. 
 
Pleural effusions are often observed after uncomplicated cardiac surgery[3, 4].  It is estimated that 
about half of patients undergoing cardiac surgery will have a postoperative pleural effusion about a week 
after surgery[5].  The majority of these are small; characterized as blunting of the costophrenic angles with 
less than 25% of the hemithorax occupied by pleural fluid[5].  The general course of a postoperative pleural 
effusion has been described as bilateral initial appearance, unilateral (usually left-sided) maintenance at 
one-week, with spontaneous resolution over time[3, 5, 6].  Such pleural effusions are generally considered 
“non-specific” and thought not to require procedural intervention[7].  More recently, we have seen a limited 
management paradigm shift toward procedural intervention [e.g. thoracentesis] for non-specific pleural 
effusion at our institution. 
 
3.2 Clinical Experience with Thoracentesis for Non-Specific Pleural Effusion  
Non-specific pleural effusions are a frequent and clinically acceptable observation in patients 
following cardiac surgery at Yale - New Haven Hospital.  Approximately 2-years-ago, our Cardiac Surgery 
service began to pursue thoracentesis for an escalating number of patients with non-specific pleural 
effusion.  This change in practice stemmed from the clinical observation that a subset of patients with 
limited pulmonary reserve benefitted from removal of even small volumes of pleural fluid.  The utility of 
thoracentesis has never been formally studied in this population despite its increasing use at Yale – New 
Haven Hospital. 
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Mid-level providers from our Cardiac Surgery service have made informal observations of several 
benefits with use of thoracentesis for non-specific pleural effusion.  First, it is thought that patients with 
limited pulmonary reserve and non-specific pleural effusion have improved dyspnea after thoracentesis 
versus those who do not have procedural intervention.  An interrelated observation is shorter hospital 
length of stay.  This has been attributed to improved dyspnea leading to better participation in inpatient 
cardiac rehabilitation.  Second, it has been informally noted that patients have fewer days of postoperative 
AF after thoracentesis versus those with effusions who do not have procedural intervention.  This 
observation is said to occur in the setting of similar anti-arrhythmic dosing for all patients with 
postoperative AF.  It is thought that decreased frequency of AF also shortens patient length of stay.  Lastly, 
our mid-level providers have reported that the requirement for escalation of care [e.g. transfer to a unit 
providing a higher intensity of care] is less frequent in patients who have thoracentesis for pleural effusion 
versus those who have not. 
 
In order to better understand and characterize these observations, there are three questions that 
might be addressed.  First, how do non-specific pleural effusions develop after cardiac surgery?  Second, 
how might thoracentesis improve pulmonary dysfunction in these patients?  Third, is there formal 
retrospective evidence to support the claims of benefit at our institution?  To address these, a 
comprehensive review of the clinical literature is performed and summarized.  The basic science literature 
is also reviewed and a model for the pathogenesis of non-specific pleural effusion is proposed.  Lastly, we 
will perform a retrospective clinical study comparing outcomes of patients who had thoracentesis and 
patients who did not have procedural intervention for non-specific pleural effusion after cardiac surgery. 
 
3.3 Pulmonary Dysfunction and Recovery from Cardiac Surgery 
Pleural effusion is one of several pulmonary complications with a potential to prolong recovery after 
cardiac surgery[8].  In general, patients tend to have decreased respiratory function due to restrictive lung 
changes following cardiac surgery[9].  Impaired chest wall mechanics seem to play a significant role in 
restriction[9].  In a study of 18 cardiac surgery patients with normal preoperative pulmonary function 
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testing (PFT) by Van Belle, et al; total lung capacity (TLC), 1-second forced expiratory volume (FEV1), 
and functional residual capacity (FRC) were significantly impaired a week after surgery [(6.2 vs. 4.6L; p < 
0.0001), (3.4 vs. 2.4L; p < 0.0001), (3.2 vs. 2.6L; p < 0.001) respectively][10].  The same study reported 
significantly negative frequency dependent resistance by body-plethysmography, indicating an additional 
component of airway obstruction[10].  The authors suggested that, in addition to impaired chest wall 
mechanics, extravascular lung fluid and atelectasis likely play roles in decreased respiratory function[10]. 
  
The restrictive changes in ventilation associated with pleural effusion are generally proportional to 
the size of the effusion[11, 12].  Perhaps the reason why non-specific pleural effusions are thought not to 
require intervention is that they are characterized as small and have a tendency to spontaneously resolve.  
But this generalization may be misleading in terms of predicting postoperative course after cardiac surgery.  
In a large study of 2,892 patients by Labidi, et al, 192 patients (7%) were found to have “significant” 
pleural effusions after cardiac surgery[4].  The term “significant” was not well defined and although the 
majority had symptoms, not all patients were described as symptomatic[4].  Of the symptoms reported, 
70% had shortness of breath, 56% had cough, 48% had bronchial secretions, 34% were tachypneic, and 
23% had chest pain[4].  In this series, more than half of patients had small effusions occupying less than 
25% of the hemithorax and 21% required multiple interventions[4].  The symptomology of small pleural 
effusions tends to be similar to larger effusions.  In a 29-case series of effusion occupying more than 25% 
of the hemithorax by Rodriguez and Light, et al, 76% of patients with a large effusion complained of 
shortness of breath, 10% complained of chest pain, and 3% complained of fever at 30-days[5, 13].  These 
studies suggest that size is not proportional to symptoms. 
 
Symptoms of pulmonary dysfunction after cardiac surgery are known to prolong hospital stay and 
increase costs of care[8].  Pleural effusion has been shown as an independent risk factor for prolonged 
recovery after cardiac surgery[3-6, 13, 14].  Labidi, et al, reported both longer ICU stay (142 ± 643 hrs 
versus 35 ± 565 hrs; p < 0.05) and longer hospital stay (16.2 ± 20.9 versus 7.5 ± 8.6 days; p < 0.001) for 
192 patients with pleural effusion requiring thoracentesis after cardiac surgery[4].  This same study 
reported that the majority of patients had small pleural effusions occupying less than 25% of the 
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hemithorax[4].  These data suggest that non-specific [e.g. small] pleural effusions may also be associated 
with longer periods of stay and a higher intensity of care in the postoperative period.    
 
3.4 Preoperative Risk Factors for Pleural Effusion 
There is limited data on preoperative risk factors associated with pleural effusion after cardiac 
surgery[4, 15].  In a study of 2,892 cardiac surgery patients by Labidi, et al, postoperative pleural effusion 
was more prevalent in patients with comorbid diagnoses of congestive heart failure (9% vs. 4%), peripheral 
vascular disease (22% vs. 11%) and atrial fibrillation (10% vs. 5%) versus those without effusion[4].  In 
terms of heart failure, the preoperative ejection fractions (EF) for patients in the effusion group were 
clinically similar (56% vs. 59%)[4].  The number of patients with an EF less than 40% was also slightly 
higher in the effusion group (14% vs. 8%)[4].  Diuretics, anticoagulants, anti-platelet agents, and anti-
arrhythmic agents were also associated with pleural effusion in the Labidi study[4].  Whether preoperative 
conditions or their management is more associated with developing postoperative pleural effusion remains 
unclear. 
 
However, Jensen and Yang found no association between preoperative heart failure and 
postoperative pleural effusion in a retrospective study of 315 CABG patients[15].  Atrial fibrillation and 
peripheral vascular disease were not among diagnoses investigated in this study[15].  From a more practical 
standpoint, the attributable risks for postoperative pleural effusion in terms of the comorbidities studied are 
low in both studies[4, 15].  The number of patients included in the Labidi study was an order of magnitude 
larger than the Jensen study, which may have been why they had more statistically significant 
differences[4, 15].  One criticism that we find with the Labidi study is the number of comparisons made 
without correction for the family-wise error rate.  Perhaps using a Bonferroni or other corrective method 
would have reduced the number of significant differences.  If there were a causal relationship between 
preoperative comorbidities and postoperative pleural effusion, the attributable risks are small in the best 
studies available. 
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3.5  Intraoperative Risk Factors for Pleural Effusion 
3.5.1 Topical Hypothermia 
Topical hypothermia is thought to provide a cardio-protective benefit during surgery but it is now 
used less frequently due to concern over pulmonary complications[16-19].  Myocardial hypothermia 
decreases cellular metabolism, prevents cellular damage from anoxia, and reduces the rigidity of 
contraction[16].  A study by Allen, et al, of 150 nonrandomized consecutive patients showed that topical 
hypothermia with ice-slush versus no cooling was associated with an increase in postoperative pleural 
effusion prior to discharge (RR = 2.8, p < 0.05)[17].  The ice-slush technique also was associated with 
increased length of stay (11.2 vs. 8.5 days; p < 0.05)[17].  Intraoperative ice-slush was also associated with 
postoperative pleural effusion in a study of 505 nonrandomized consecutive patients by Nikas, et al (RR = 
2.4, p < 0.0001)[18].  These patients also received concurrent systemic hypothermia and cold 
cardioplegia[18].  Authors in both studies concluded that phrenic nerve dysfunction results in atelectasis 
which then leads to pleural effusion[17, 18].  Intraoperative stretch injury was also proposed as a 
mechanism for phrenic nerve dysfunction by these authors as a similar cause of atelectasis and subsequent 
pleural effusion[19, 20]. 
 
Pleural effusion in patients with true diaphragm paralysis (e.g. myasthenia gravis) has been 
demonstrated in ICU patients[21].  How this exactly occurs has also not been fully described.  One 
explanation is that elevation of the hemi-diaphragm by elastic recoil of local lung segments attached to the 
visceral pleura may increase negative pressure in the adjacent pleural space[22].  Mechanically increasing 
negative pressure in the pleural space would potentiate the hydrostatic driving force for fluid filtration[23].  
If filtration exceeds drainage, pleural effusion results.  An alternative explanation might be 
ventilation/perfusion changes in collapsed lung segments leading to localized hypoxemia and lung edema.  
The ensuing inflammatory response may increase the permeability of the visceral pleura[23, 24].  This 
would lead to a functional connection between lung and pleural compartments not present in the normal 
physiologic state[23].  Rising interstitial fluid pressure in the lung would first cause alveolar collapse (e.g. 
atelectasis).  At a certain threshold based on the relative permeability of the visceral pleura, fluid will 
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overflow causing increased fluid filtration into the pleural space[23].  If fluid filtration overwhelms 
lymphatic drainage of the pleural space, effusion will develop.   
 
One point of contention for the topical hypothermia data is whether or not phrenic nerve 
dysfunction is present at all[25].  In a study by Wilcox, et al, 93% of 52 postoperative patients receiving 
topical hypothermia developed left lung atelectasis but less than 10% were found to have unequivocal 
phrenic nerve dysfunction in the early postoperative period[25].  Multivariate analysis of intraoperative 
factors showed that number of grafts, operative time, bypass time, opening of the pleura, non-use of a right 
atrial drain, non-use of a polystyrene shield, and body temperature were predictive for the degree of left 
lower lobe atelectasis[25].   If there is no disruption of phrenic nerve function but atelectasis and pleural 
effusion still occurs, then another mechanism is implicated. 
 
Inflammation might better explain both the development of atelectasis and it’s relationship with 
pleural effusion.  Although the association between topical hypothermia, atelectasis, and pleural effusion is 
strong, its interdependence on diaphragm paralysis is less convincing.  Cardiopulmonary bypass, aortic 
cross-clamp time, and positive end expiratory pressure during postoperative mechanical ventilation are also 
associated with lung injury and inflammatory changes[26, 27].  Similarly, these risk factors are associated 
with atelectasis and pleural effusion[26, 27].  Exactly how lung injury would be potentiated by topical 
hypothermia is unclear.  It is possible that the use of topical hypothermia might be a confounder for factors 
that are also strongly associated with pleural effusion.  In fact, the Nikas study found that cross-clamp time 
was elevated (49 vs. 43 min) for those receiving topic hypothermia[18].  The routine use of topical 
hypothermia is no longer standard of care due, in part, to its relationship with pulmonary complications.  
However, reexamining these data has been valuable in understanding the plausibility of lung inflammation 
as part of the pathogenesis of pleural effusion. 
 
3.5.2 Cardiopulmonary Bypass  
Another intraoperative risk factor associated with pleural effusion is cardiopulmonary bypass 
(CPB)[8].  Volume overload in the setting of CPB has been thought an obvious iatrogenic insult because: a) 
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patients receive an average of 3-4L of crystalloid and colloid fluids during cardiac surgery; b) patients can 
present with some degree of preoperative fluid overload in the setting of heart failure; c) comorbid renal 
disease is a common presentation for these patients; and d) pleural effusion is common after cardiac 
surgery[4, 9, 28, 29].  Pulmonary edema is also associated with CPB[8, 30-33]. It has been suggested that 
the pathogenesis of pulmonary edema and pleural effusion may be interrelated.[8]. 
 
Intravascular hydrostatic forces associated with volume overload may cause both pulmonary 
edema and pleural effusion[34]. The lung and pleural spaces are separate compartments in the normal 
physiologic state[23].  In volume overload, elevated pulmonary capillary pressure can exceed osmotic 
counter pressure in the lung interstitium[34].  This drives fluid into the lung interstitium.  Under normal 
circumstances, lymphatic drainage functions as a recruitable homeostatic mechanism for recovery[23].  
Fluid accumulates when the lymphatic reserve capacity to clear fluid from the lung interstitium is 
overwhelmed[23, 34].  Pulmonary edema can occur rapidly because the lung compartment is relatively 
non-compliant[23].  The pleural space accumulates fluid by a similar mechanism[34].  Pulmonary and 
central venous pressures are elevated in the setting of volume overload and this increases the filtration rate 
of pleural fluid[23].  When the osmotic counter pressure and lymphatic clearance reserves are 
overwhelmed, pleural effusion results[34]. 
 
Volume overload may only be part of a more complete explanation for pleural effusion after 
cardiac surgery.  In a study of 10 patients by Hachenberg, et al, intra-thoracic thoracic blood volume 
(ITBV), pulmonary blood volume (PBV), and extravascular lung water (EVLW) were found to be elevated 
immediately following separation from CPB[29].  However, at 4-hrs and 24-hours after separation, ITBV 
and PBV remained elevated while EVLW decreased to preoperative levels[29].  The authors concluded that 
postoperative hypoxemia resulting from fluid overload was not due to pulmonary edema and that 
homeostatic mechanisms were maintained after CPB[29].  Both the lung and pleural compartments restore 
homeostatic fluid balance through recruitment of the lymphatic system[23].  If the homeostatic mechanism 
for recovery from pulmonary edema is maintained, it is reasonable to assume that this is also maintained in 
the pleural space [e.g. the lymphatics are not interrupted]. 
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How pleural effusion still develops if there is relative capacity for fluid clearance requires further 
consideration.  The observation that EVLW is reduced within 4-hours of separation from CPB (detailed 
above) might represent evidence for a non-physiologic lung compartment drainage mechanism that is not 
recruitable by the pleural compartment[29].  One explanation proposed in chronic heart failure models is 
that there is a pathophysiologic connection developing between the lung and pleural compartments [e.g. the 
relative permeability of the visceral pleura increases][23].  By this mechanism, EVLW would be reduced as 
pleural fluid filtration increases.  Wiener-Kronish, et al, demonstrated that lung edema induced by 
inflammatory lung injury resolves by drainage into the pleural space through the visceral pleura in 
sheep[35, 36].  Another explanation may be that the lymphatics of the pleural space are selectively 
interrupted by an IMA takedown.  However, there is no evidence to suggest that pleural effusion lateralizes 
to the side of IMA takedown[37]. 
 
Inflammatory changes in the lung have been proposed to increase the permeability of the visceral 
pleura[23, 35, 36].  Acute systemic inflammation and lung inflammation have been shown a consequence 
of CPB[30-33].  Intubation with positive pressure ventilation is another source of inflammation and 
pulmonary dysfunction[38].  The Alveolar-arterial (A-a) gradient is more severe after CPB than general 
surgical procedures, which suggests a higher degree of lung injury and shunt fraction after CPB[39].  The 
presence of inflammatory mediators in bronchoalveolar lavage (BAL) fluids after separation from CPB also 
supports local lung inflammation[26].  Markers of systemic inflammation including compliment activation 
and leukocyte activation have been shown in patients during and immediately after separation from 
CPB[40, 41].  The compelling evidence for the association between CPB, lung, and systemic inflammatory 
changes makes it a more reasonable explanation for the contribution of volume overload to pleural 
effusion. 
 
3.5.3 Surgical Trauma and Pleurotomy 
Direct surgical trauma to the pleura has also been identified as a risk factor for postoperative 
pleural effusion.  Patients who undergo CABG using left internal mammary artery (LIMA) grafting versus 
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saphenous vein grafting (SVG) techniques have been shown to be at greater risk for pleural injury[42-44].  
The risk of opening the pleura is higher during IMA takedowns and therefore, it has been identified as an 
iatrogenic source of pleurotomy[42]. 
 
In a study comparing 200 patients by Hurlbut, et al, a significantly larger proportion of patients 
having undergone LIMA takedown manifested pleural effusion on POD6 versus those who had a 
saphenous vein graft (84% vs. 47%, p < 0.05)[42].  Among symptomatic patients, the amount of fluid 
removed was also larger (1,413 vs. 1,028 mL; p < 0.01) and this group had a significantly higher 
requirement for re-intervention with thoracentesis (4% vs. 0%, p = NR)[42].  There was no difference in 
atelectasis between the two groups at various perioperative time intervals[42].  Shielding of the 
myocardium with a cooling jacket and use of a phrenic nerve shield was employed to avoid myocardial 
damage and avoid postoperative phrenic nerve associated atelectasis[42].  Another study by Jain, et al, of 
152 patients showed similar results for development of postoperative pleural effusion in LIMA versus SVG 
techniques (55% vs. 35%, p < 0.05)[44].  A third prospective study by Ali, et al, of 280 nonrandomized 
patients showed a significantly higher number of POD3 pleural effusions for LIMA takedown patients 
where the pleura were surgically violated, versus those in whom the pleura was left intact (5% vs. 20%, p < 
0.05)[43].  However, in another study of 30 patients, Vargas, et al, found no association between surgical 
violation of the pleura and the development of pleural effusion[14].  One consideration for this finding 
might be the relatively few patients studied. 
 
There is further cytological evidence for pleural violation as a risk factor for the development of 
postoperative effusion in CABG patients.  In a study of pleural fluid from symptomatic patients post-
CABG with IMA takedowns, Sadikot, et al, observed a mean red blood cell count of 706 X 1012/L, 
corresponding to a hematocrit of approximately 5%[37].  Further support for the finding of bloody effusion 
was described in Labidi’s study for symptomatic effusion patients prior to POD15[4].  The type of surgical 
procedure was not reported for those patients in whom pleural fluid was analyzed and no reference is made 
as to what proportion had violation of their pleura[4].  A hemothorax is defined as a pleural effusion with a 
hematocrit of >50% of the blood hematocrit[45, 46].  If the approximate observed hematocrit in these 
Page 16 of 67 
  
patients is around 5%, we can assume that there is an additional source of fluid effusion.  Sadikot observed 
early pleural effusions as exudative by Light’s Criteria with an approximate hematocrit of 5%[37].  
Therefore, it would be reasonable to think that there is another process causing dilution.  It is yet unknown 
exactly how this occurs, whether at the site of pleurotomy or by another mechanism such as increased 
pleural fluid filtration. 
 
From the current clinical literature, we can speculate that the major contributing etiologies for 
pleural effusion after cardiac surgery are intraoperative in nature.  These etiologies are CPB and 
pleurotomy.  Preoperative risk factors, if contributory, seem to have a small attributable risk.  The broader 
mechanism for the contribution of CPB to pleural effusion is volume overload in the setting of an 
inflammatory response to lung injury.  Pleurotomy is also a potential modifying effect for developing 
pleural effusion whereby pleural injury and bleeding result in increased fluid filtration into the pleural 
space.  The common pathogenesis for pleural effusion from these risk factors suggests interrelated lung and 
pleural inflammation.  A review of the current basic science research hereafter details evidence that 
elaborates this further.  This evidence is summarized into a more comprehensive model for the 
inflammatory pathogenesis of pleural effusion after cardiac surgery.  A comprehensive understanding of 
the pathogenesis for pleural effusion after cardiac surgery would be useful in evaluating therapies to 
address this condition, including thoracentesis. 
 
3.6 Pathogenesis for Non-Specific Pleural Effusion after Cardiac Surgery 
Inflammatory processes are the underlying basis for many physiologic and pathologic 
processes[47].  Given the proximity of the serous pleural layers to local the microcirculation, experts 
speculate that the number of immune cells normally present in the pleural space represent an ongoing 
physiologic inflammatory process[24].  There is general agreement that the pathologic processes that 
underpin most etiologies of pleural effusion [e.g. parapneumonic, asbestosis, etc.] are inflammatory in 
nature[24].  Cytologic characterizations of inflammation have already been described for several 
conditions[24].  These include complicated parapneumonic effusion/empyema, tuberculosis, asbestosis, 
pleurisy, malignant mesothelioma, metastatic carcinomatosis, and pleurodesis[24].  The inflammatory 
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processes associated with non-specific pleural effusion after cardiac surgery has not yet been fully 
described.  Based on the current literature, we can build a broad framework of pleural inflammation for 
effusion in this clinical setting. 
 
3.6.1 Inflammation: Physiologic Response and Pathologic Consequences 
Medzhitov’s 2008 Nature Review Article frames inflammation in terms of inflammatory triggers 
that lead to a purposeful physiologic response[47].   These physiologic responses are generalized.  In some 
circumstances they can have consequences that result in pathology[47].  One example is tissue injury 
leading to inflammation as a tissue repair response[47].  The consequences of this response that are 
occasionally observed are fibrosis, metaplasia, or sometimes neoplasia[47].  Another example is 
physiologic tissue stress or malfunction that leads to inflammation as an adaptation to stress and restoration 
of a homeostatic state[47].  Occasionally, clinicians observe shifts in the original homeostatic set points, 
diseases of homeostasis [e.g. insulin insensitivity/DM2], or autoimmune diseases[47]. 
 
According to Medzhitov’s framework, large ranges of mediators that form complex regulatory 
networks would coordinate inflammatory responses[47].  One approach to understanding these complex 
networks is to break them down into individual processes characterized by inducers, sensors, mediators, 
and effectors[47].  As an inciting signal, endogenous inducers [e.g. surgically altered tissues, edema] would 
require a sensing mechanism to propagate a response[47].  Modulation of sensors can lead to expression 
and/or de-sequestration of mediators that ultimately act on effectors[47].  Mediators can be cell derived, 
tissue derived, plasma derived or derived from the extracellular matrix (ECM) [47].  Effectors can also be 
cells, tissues, plasma, or the ECM[47]. A process associated with an inflammatory response can 
simultaneously interact with other sub-routines as a network[47].  Further, processes can interact in series 
as part of an ongoing response[47].  These interactions are thought to be governed by the balance between 
pro- and anti-inflammatory signals[47].  In so much as pro-inflammatory signals can lead to physiologic 
responses such as tissue repair and alterations in homeostasis, anti-inflammatory signals have the potential 
to lead to resolution of inflammation or return to physiologic homeostatic set points[47]. 
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3.6.2 Lung Injury, Inflammation and Non-Specific Pleural Effusion 
Pleurotomy is a traumatic inflammatory trigger for pleural repair.  The most obvious inducer to be 
considered is the surgically induced epithelial-mesenchymal interaction[47].  Epithelial cells are 
physiologically separated from mesenchymal cells by a basement membrane[47].  The sensors associated 
with connecting these two tissue layers are poorly characterized.  However, some evidence supports pleural 
tissue macrophages (pMϕ) as having a large role in coordinating the inflammatory response[48].  pMϕ have 
been shown to produce significant quantities of the chemokine mediators interleukin-1β (IL-1β) and tumor 
necrosis factor-α (TNF-α) in murine pleurisy models[49].  IL-1β and TNF-α were further shown to induce 
mesothelial cells to produce the mediators macrophage chemo-attractant protein-1 (MCP-1), macrophage 
inflammatory protein-1α (MIP-1α), MIP-2, KC and IL-8[48].  These chemokine mediators are known to 
recruit effector polymorphonuclear neutrophils (PMNs) to damaged tissues from the plasma pool[48]. 
 
Volume overload in the setting of CPB may cause increased fluid filtration into the pleural 
space[28].  Increased visceral pleura permeability in the setting of lung injury may potentiate this effect.  
Massoudy, et al, demonstrated the lung as an ongoing site of platelet sequestration, retention of activated 
PMNs, and production of cytokines (IL-6, IL-8)[30].  They were able to assess this through right atrial 
(RA) and pulmonary vein (PV) sampling before and after pulmonary passage [e.g. removal of cross clamp 
during CPB[30].  Sampling of BAL fluid after separation from CPB also supports the presence of these 
cytokines in increased concentration compared to plasma[26].  Retention of leukocytes in the pulmonary 
vasculature following pulmonary passage, combined with elevated cytokines, indicates that exposure of the 
sub-endothelial ECM is one potential inducer.  Factor XII senses vascular endothelial damage through 
activation; this occurs through contact with collagen and the ECM[47].  Activated factor XII initiates the 
four proteolytic cascades known to generate the acute phase response[47].  The tunica media of blood 
vessels secretes IL-6 as a pro-inflammatory cytokine in response to endothelial damage[50].  
 
The increased levels of IL-6 shown in the Massoudy study are of some interest[30].  Endothelial 
cells are important effectors for IL-6/sIL-6α (soluble IL-6) in that they increase expression of intracellular 
adhesion molecule 1 (ICAM-1)[51].  ICAM-1 expression enables endothelial cell regulation of leukocyte 
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recruitment[51].  Additionally, IL-6 promotes the redistribution of VE-cadherin on endothelial cells[51].  
This redistribution increases vascular permeability[51].  Moreover, the role of IL-6 is actively being studied 
for its contribution to the progression of malignant ascites in ovarian cancer and its effect on peritoneal 
permeability[51].  This interaction may be an important promoter of capillary leakage, pulmonary edema, 
and permeability of the visceral pleura.  The net result would be pleural effusion with extravasation of 
PMNs into the pleural space.  
 
The recruitment of PMNs to the pleural space after trauma is an evolutionary response with 
pathologic consequences in the perioperative setting.  In contrast to surgical intervention, penetrating 
trauma to the pleura (or lung) outside of a hospital is usually accompanied by inoculation with bacteria[50].  
The normal physiologic immune response is to control infection after trauma[50].  PMNs function as 
effectors by de-granulation; specifically, they release cytotoxic and histotoxic substances as a means of 
bactericide[50].  This endogenous insult propagates serosal inflammation and a high degree of metabolic 
activity by mesothelial cells[52, 53].  Loosening of tight and gap junctions along the vascular endothelium 
potentiates the migration of circulating Mϕ cells into the pleural space.  This increased permeability also 
increases filtration of fluid into the pleural space.  Once in the pleural space, PMNs do not return to the 
blood stream[49].  These cells will undergo apoptosis and their remnants removed by Mϕ phagocytosis 
over time[49].  In this framing, PMN degranulation and apoptosis become mediators for mesothelial 
effector cells.  Continuous stimulation of mesothelial cells and leukocyte migration likely potentiates the 
maintenance of pleural effusion. 
 
Cytological profiles for pleural fluid that are consistent with our inflammatory model have been 
described for patients after cardiac surgery[37].  Sadikot, et al, have shown significant differences to exist 
between pleural fluids evacuated from patients during early and late periods post CABG[37].  Early 
effusions (<30 days) have greater levels of neutrophils versus late effusions (0.242 vs. 0.8 X 109/L), which 
supports an early PMN response[37].  Late effusions have lymphocyte predominance (0.68 vs. 0.125 X 
109/L, p<0.001).  The later finding supports a humeral response[37, 49].  These clinical observations 
suggest that there are both acute phase and humeral responses that involve the pleural space. 
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The complete mechanism of resolution of pleural effusion after cardiac surgery is currently 
unknown.  The metabolic profiles of mesothelial cells during effusion suggest these cells play a role in 
recruitment of circulating Mϕ cells[52, 53].  Recruited circulating Mϕ cells are typically responsible for 
phagocytic removal for apoptotic PMNs (so called, efferocytosis); but this has not been fully elucidated for 
the pleural space.  Study of rat pleurisy models by Muria, et al, has suggested that PMNs have an extended 
life in the pleural space and apoptotic activity begins very shortly after recruitment to the pleural space[49].  
In small animal models of pleural injury, it has also been demonstrated that activated tissue Mϕ cells 
migrate from the pleural space to regional lymph nodes to potentiate a humeral immune response[49].  
Therefore, reducing stimulation of tissue Mϕ by leukocytes in the pleural space may reduce the persistence 
of effusion and blunt the development of a humeral response. 
 
Our interpretation of the literature is that the pathogenesis of non-specific pleural effusion after 
cardiac surgery is interrelated lung and pleural acute phase inflammation that can evolve into a humeral 
response.  The presence of apoptotic neutrophils in the pleural space could be a propagating mechanism for 
pleural inflammation and effusion.  Prolonged pleural inflammation may also increase the likelihood a late 
humeral response by an unknown mechanism.  If this is the case, reducing PMN recruitment into the 
pleural space, or removing apoptotic PMNs from the pleural space might shorten the duration of pleural 
inflammation and effusion.  Further, it might also blunt the development of a humeral response.  Heidecker 
and Sahn suggested that early [e.g. non-specific] and late pleural effusions were based on different 
etiologies with different pathogenesis[54].  We speculate that an evolving inflammatory response might be 
a better explanation. 
 
3.6.3 Post-pericardiotomy Syndrome, Atrial Fibrillation and Pleural Effusion 
Post-pericardiotomy syndrome (PPS) is a condition that affects 10-40% of patients after cardiac 
surgery[55].  PPS is cited to be the result of a humeral inflammatory response with a poorly understood 
pathogenesis[55, 56].  The syndrome is characterized by a specific constellation of symptoms at 
approximately 1-6 weeks after any type of pleuro-pericardial trauma[55].  The generally accepted 
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diagnostic criteria includes presentation with 2 of the following: 1) fever; 2) pleuritic chest pain; 3) rubs 
(pericardial or pleural); 4) pericardial effusion; or 5) pleural effusion (with or without elevated CRP)[55, 
57].  The progression of the syndrome is thought to start with an iatrogenic trigger (cardiac surgery) and 
has a “sub-clinical” latency period until symptoms appear approximately 2-3 weeks later[55].  The “sub-
clinical” latency period is often characterized by maintenance or development of a late pleural effusion[5].  
Symptoms of PPS can be important because approximately 2-3% of symptomatic patients go on to develop 
constrictive pericarditis[55, 56].  As such, these patients may require more vigilant follow up after 
surgery[55, 56]. 
 
We are interested in the PPS for several reasons that are based on our understanding of pleural 
effusion after cardiac surgery.  First, it is estimated that up to 85% of patients with a diagnosis of PPS 
present with a pericardial effusion but up to 90% will present with a pleural effusion[56].  Second, on-
treatment analysis in the COPPS-2 randomized controlled trial showed that perioperative colchicine 
reduces pericardial effusion and pleural effusion after cardiac surgery (relative risk reductions 44%, 52% 
respectively)[57].  The mechanism of action for colchicine includes inhibition of TNF-α synthesis by 
macrophages and down regulation of TNF-α-receptor expression on both macrophages and endothelial 
cells[58].  Additionally, colchicine inhibits microtubule assembly in PMNs, which blunts mobilization[58].  
Therefore, the expected effect would be reduction of tissue macrophage activation and PMN recruitment to 
the pleural space.  Considering our current model, we might have expected a reduction in pleural effusion 
from this therapy.  Unfortunately during the COPPS-2 trial, colchicine had to be discontinued in 22% of 
patients due to gastrointestinal side effects[58].   
 
Third, we are interested in the 45% reduction in postoperative atrial fibrillation (NNT=11) found 
on on-treatment analysis from the COPPS-2 trial[57].  The authors did not comment on the covariance of 
reduction in pleural effusion and atrial fibrillation.  However, our Cardiac Surgery service has anecdotally 
noted reductions in maintenance of atrial fibrillation with early thoracentesis on patients with postoperative 
pleural effusions.  The authors of the COPPS-2 trial indicated that there were two possible mechanisms for 
reduction in postoperative AF in patients receiving colchicine[57].  These included reduction of calcium-
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induced ectopy by inhibition of microtubule assembly and by reduction of PMN recruitment to damaged 
cardiac tissue[57]. 
 
Further, a retrospective multivariate analysis of 969 patients by Stamou, et al, found that 
postoperative pleural effusion was an independent risk factor for atrial fibrillation (RR = 3.2, 95% CI 1.0-
9.4, p=0.03)[59].  Pericardial effusion is also a known risk factor for AF and up to 63% of patients maintain 
a sub-clinical pericardial effusion 1-week after surgery[60].  Vargas, et al, have previously demonstrated 
that the persistence of pericardial effusion is dependent on the persistence of pleural effusion after 
myocardial revascularization[61].  Perhaps this is explained by relationship between the lymphatic systems 
for both the pericardium and pleurae[62].  The majority of the pericardium and left chest is drained through 
the upper thoracic duct.  This route has a high recruitable capacity for pleural drainage but recruitment may 
impact the system’s capacity for pericardial drainage[23].  Mechanical compression activates pericardial 
mesothelial cells (by effusion) and promotes pericardial inflammation[52].  If pericardial effusion is a risk 
factor for AF and resolution of pericardial effusion is dependent on resolution of pleural effusion, it would 
be reasonable to think that treating pleural effusion may have a downstream effect on resolution of AF.  
Whether or not draining the pleural space has an impact on prevalence of postoperative AF is unknown. 
 
3.7 Thoracentesis: A Role in Non-Specific Pleural Effusion? 
The clinical considerations for use of thoracentesis in non-specific pleural effusion after cardiac 
surgery should weigh risk of injury against the potential for benefit.  Up until the past 10-15 years, the 
historical safety profile of thoracentesis had been poor.  In 1993, a review by Bartter, et al of 337 
thoracenteses performed without imaging guidance cited a major complication rate of 4-30%[63].  These 
complications consisted primarily of pneumothorax but also included hemothorax, splenic laceration, and 
even a retained surgical instrument[63].   The overall percentage of patients requiring intervention for 
complications was 6%; and these included tube thoracostomy, blood transfusion, and thoracotomy[63].  
There were also several deaths in critically ill patients requiring thoracentesis[63]. 
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However, the sensitivity and increasing adoption of thoracic ultrasound has dramatically changed 
the safety profile of thoracentesis over the last decade.  For cardiac surgery patients, this has been realized 
in terms of both improved “real-time” detection of pleural effusions and reduced complications[64, 65].   In 
a recent study by Usta, et al, 135 patients requiring thoracentesis had their procedures performed under 
ultrasound guidance[65].  The resulting therapeutic yield was 100% [e.g. fluid was obtained from patients] 
with a 0% complication rate[65].  The overall reduction in complications with thoracic ultrasound has led 
our Cardiac Surgery service to reexamine the utility of thoracentesis in patients with non-specific pleural 
effusion. 
 
The generally accepted therapeutic mechanism for thoracentesis is the reduction of restricted 
ventilation[11, 12].  Symptoms of restricted breathing tend to increase with the size of pleural effusion[11, 
12].  However, symptoms of respiratory dysfunction are independent of size in non-specific pleural 
effusion[3-6, 13].  These symptoms are clinically significant and negatively correlate with outcomes.  In 
the previously cited study by Usta, et al, thoracentesis was reserved for patients with a pre-procedure 
pleural fluid volume estimate of >480mL[65].  Patients undergoing thoracentesis were discharged on POD 
9–10, whereas patients with smaller effusions that were managed with diuretics stayed 3 ± 1.5 days 
longer[65].  This suggests that patients with smaller pleural effusions might have had clinically significant 
symptoms that led to longer hospital stay. 
 
Clinical benefits for thoracentesis in patients with non-specific pleural effusion after cardiac surgery 
have not been described.  Based on the current literature, we can only speculate that patients with non-
specific pleural effusion might benefit from thoracentesis.  Symptomatic improvement after thoracentesis is 
generally correlated with increasing volume of pleural fluid removed[11, 12].  However, benefit in non-
specific pleural effusion would have to be realized from a different mechanism because the effusions are 
small.  Our interpretation of the current literature is that the pathogenesis of non-specific pleural effusion 
after cardiac surgery is interrelated lung and pleural inflammation.  The presence of apoptotic neutrophils 
in the pleural space is a propagating mechanism for lung and pleural inflammation.  Symptoms of 
respiratory dysfunction, including dyspnea, are a known consequence of lung and pleural 
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inflammation[32].  Therefore, we can speculate that early reduction of PMN burden in the pleural space 
with thoracentesis might shorten the duration of lung and pleural inflammation, as well as pleural effusion.  
Thoracentesis might also result in fewer days in atrial fibrillation if treating a non-specific pleural effusion 
is associated with resolution of sub-clinical pericardial effusion. 
 
4 Study Design, Specific Aims, and Hypothesis 
4.1 Statement of Purpose and Specific Aims 
This study retrospectively compares clinical outcome measures for cardiac surgery patients with 
non-specific postoperative pleural effusions, some of whom had procedural intervention with thoracentesis 
and others that did not.  The use thoracentesis in this setting is currently based on clinical judgment that 
weighs established risk against poorly described benefit.  Complications from thoracentesis performed by 
our Thoracic Interventional Program Service (TIPS) under transthoracic ultrasound guidance are generally 
regarded as infrequent and are beyond the scope of this study.  Some cardiac surgeons assert that there is 
benefit to early thoracentesis for non-specific pleural effusion in specific cases.  However, the current 
literature neither provides sufficient data on the frequency of improved dyspnea [e.g. clinical benefit] after 
thoracentesis, nor formal comparisons of clinical outcomes to fully support expanded use in this 
population.  Better understanding of these outcomes to inform clinical judgment is emerging as a clinical 
imperative at our institution. 
 
The purpose of this study is to 1) measure the frequency of improved dyspnea after thoracentesis on 
cardiac surgery patients with non-specific pleural effusion; and 2) compare clinical outcomes between 
patients who had thoracentesis versus those who did not.  The scope of clinical outcomes studied is 
informed by the current literature but limited to the anecdotal clinical observations reported by mid-level 
providers at Yale - New Haven Hospital.  To our knowledge, this is the first comparative evaluation of 
outcomes for “therapeutic” thoracentesis in cardiac surgery patients with non-specific pleural effusion. 
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4.2 Study Design 
A Case – Control design is chosen for this study.  Cardiac surgery patients with postoperative 
pleural effusion who had thoracentesis in the early postoperative period (Cases) are matched by age and 
operation with patients who did not undergo thoracentesis (Controls). 
 
We have chosen to match patients by age and operation for several reasons.  First, surgical trauma 
and CPB have been identified as risk factors for both developing and maintaining a pleural effusion 
[Section 3.4].  If an outcomes comparison is to be made regarding postoperative pleural effusion, the extent 
of surgical trauma and general use of CPB should be comparable.  There is inconsistent evidence for time 
on CPB as risk factor for postoperative pleural effusion and for this reason we consider this less 
contributory[4, 25].  Second, the Cardiac Surgery team at Yale – New Haven Hospital acknowledges 
differences in length of stay that is operation specific (e.g. CABG patients tend to have shorter lengths of 
stay than CABG patients with concurrent AVR).  Third, there is insufficient data to control for the potential 
the modifying effects of specific operations on the development or persistence of AF in the postoperative 
period.  Therefore, matching by operations may provide a more meaningful comparison between cases and 
controls.  Fourth, age is a known risk factor for both length of stay and the development of AF[66].  
Matching by age would attempt to eliminate this source of selection bias.  Outcomes experienced by 
patients are summarized and where appropriate, compared between Case and Control groups. 
 
For this analysis, 30 patients were selected based on the Statistical Considerations outlined in 
Section 5.7.  Medical chart data is collected from documented outcomes observed, including a surrogate 
measure of dyspnea, hospital length of stay (LOS), rate of escalation of care, days in atrial fibrillation, 
markers of systemic inflammatory response, and requirement for further outpatient management of pleural 
effusion after discharge.  Data is collected from a population of patients after cardiac surgery by a single 
surgeon to limit inter-operator variability and at a single institution to limit variability in postoperative care. 
 
Observational end points are the subject of this study for several reasons: 1) Mid-level providers 
reported their informal observations for patients that have already received care at our institution, 2) The 
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clinical outcomes of interest are sufficiently well documented in the electronic medical record, 3) There is 
currently a lack sufficient clinical data to reasonably justify a prospective study at this point; and 4) 
Outcomes data can be used in further hypothesis refinement for potential prospective trials if warranted. 
 
4.3 Hypothesis 
We believe that the majority (>50%) of patients who undergo thoracentesis for non-specific pleural 
effusion have improved dyspnea.  We will formally measure the frequency of improved dyspnea 
experienced by these patients to support this assertion.  In terms of comparative clinical outcomes, the null 
hypothesis is that there is no difference between patients having thoracentesis versus no procedural 
intervention for non-specific pleural effusion after cardiac surgery in terms of:  1) the frequency of 
improved dyspnea, 2) LOS, 3) requirement for escalation of care, and 4) days of AF.  The alternative 
hypothesis is that thoracentesis improves these clinical outcomes.  Our argument for an alternative 
hypothesis is based on: a) increased length of stay is associated with persistence of dyspnea and AF[65, 
67], b) decline in pulmonary status is a common reason for escalation of care at our institution, and c) our 
current model of inflammation for non-specific pleural effusion after cardiac surgery suggests that 
persistence of effusion and days in AF might be reduced by removal of PMNs from the pleural space. 
 
4.4 Study Endpoints 
Primary Endpoint:  What is the frequency of improved dyspnea after thoracentesis for non-specific 
pleural effusion after cardiac surgery? 
Secondary Endpoint:  Is there a difference in postoperative length of stay for patients who had 
thoracentesis versus those who did not? 
Tertiary Endpoint:  What are the rates of escalation of care for patients who underwent 
thoracentesis and those who did not? 
Additional Endpoints:  Is thoracentesis associated with fewer postoperative days in AF in cardiac 
surgery patients? Was the medical management of AF with amiodarone in Controls and Controls different?  
Is there a difference in incidence of post-pericardiotomy syndrome?  What is the requirement for post-
discharge care of pleural effusions in those who had early thoracentesis and those who did not?  What was 
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the average hospital length of stay from intervention (thoracentesis) to discharge?  What was the 30-day 
mortality?  What was the absolute mortality? What amount of fluid is removed from patients requiring 
thoracentesis?  Were there markers of systemic inflammation during the postoperative period for Cases or 
Controls? 
 
4.5 IRB Review and Approval 
This medical record review was conducted according to the current revision of the Declaration of 
Helsinki.  The Institutional Review Board at Yale University approved the clinical study protocol prior to 
study initiation on December 14th, 2014 as HIC #1412015043.  
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5 Methods 
5.1 Roles and Responsibilities 
This project is the culmination of efforts by many individuals.  A detailed list study contributors is 
shown below (Table 1).  The medical student (David R. Kull, MPH) role was limited to the following 
work: Coordination of Research Team Contributions, Primary Authorship and Revision of Study Protocol, 
Case-Control Selection, Abstraction of Clinical Outcomes Data (All Records), Statistical Analysis of 
Outcomes Data, and Primary Authorship of Manuscript.  The medical student did not participate in the 
following activities or responsibilities: Principal Investigator, Expert Review of Study Protocol, Expert 
Review of Manuscript, Draft or Submission of HIC Documentation (based on Study Protocol). 
 
Table 1:  Key Study Personnel 
Principal Investigator: 
Umer M. Darr, MD 
Department of Surgery, Section of Cardiac Surgery 




David Kull, MPH (Medical Student) 
Yale University School of Medicine 
Role(s):  Author Protocol, Case/Control Selection, 
Records Abstraction, Data Analysis, Author 
Manuscript 
Co-Investigator: 
Gaetane C. Michaud, MD 
Dept. of Medicine, Section of Pulm. and Crit. Care 
Role(s):  Protocol Review, Manuscript Review 
 
Co-Investigator: 
Jonathan T. Puchalski, MD 
Dept. of Medicine, Section of Pulm. and Crit. Care 
Role(s):  Clinical Contributor 
Co-Investigator: 
Christina Carbone, CCRP (Research Coordinator) 
Dept. of Medicine, Section of Pulm. and Crit. Care 




Barbara Stahl, APRN, DNSc (Acute Care NP) 
Department of Surgery, Section of Cardiac 
Surgery 
Role(s):  Protocol Review 
Co-Investigator: 
Vladimir Shumaster, MD (Research Fellow) 
Department of Surgery, Section of Cardiac Surgery 
Role(s):  Protocol Review 
 
Co-Investigator: 
Kelsey Johnson, MSc, PA-C (Clinical PA) 
Department Surgery, Thoracic Interventional 
Program 
Role(s):  Protocol Review 
Study Personnel: 
Rowena Saga-Abrina, APRN (Clinical NP) 
Department of Surgery, Section of Cardiac Surgery 
Role(s):  Protocol Review 
 
Study Personnel: 
Ann Roselle, MS, PA-C (Clinical PA) 
Department of Surgery, Section of Cardiac 
Surgery 
Role(s):  Protocol Review 
Study Personnel: 
Eileen Taylor, RN, MBA 
Department of Surgery, Section of Cardiac Surgery 
Role(s): Protocol Review 
 
Thesis Sponsor: 
Frank Detterbeck, MD 
Department of Surgery, Section of Thoracic 
Surgery 
Role(s): Thesis Review 
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5.2 Study Population 
Patients who are status-post cardiac surgery, performed by a single surgeon (Umer M. Darr, MD) at 
Yale - New Haven Hospital during the two-year period commencing January 1st, 2013 and ending 
December 30th, 2014, with a radiographically evident pleural effusion were considered.  Cases and Controls 
were selected amongst patients meeting Inclusion and Exclusion Criteria (described in Sections 5.2.1 and 
5.2.2 respectively) by the procedure defined in Section 5.3.  In brief, the Case group is comprised of 
patients meeting inclusion and exclusion criteria in which thoracentesis was performed during the early 
postoperative period.  The Control group is selected amongst age and operation matched patients, who did 
not undergo early thoracentesis during the same period.   
5.2.1 Inclusion Criteria  
Subjects must meet all of the following inclusion criteria to be entered into the study:  
1. Post-primary open cardiac surgery (CABG, valve, CABG + valve, etc.) 
2. Age 40-85 years 
3. Postoperative pleural effusion in the early postoperative period (POD3 - POD7) 
5.2.2 Exclusion Criteria 
Any of the following will exclude the subject from study:  
1. Prior cardiac surgery 
2. History of pleurodesis 
3. Patients with pleural effusion known to be associated with non-cardiac related etiology (e.g. 
pancreatitis, malignancy, etc.) 
4. Operative complications (intraoperative bleeding requiring massive transfusion protocol or 
documented inadvertent intraoperative injury) 
5. Maintenance of a chest tube or tunneled pleural catheter during the early postoperative period 
6. INR > 2.5 (for Cases, at the POD of thoracentesis; Controls, the matched POD)  
 
Rationale for exclusion criteria:  The primary endpoint of the study is to formally measure the frequency of 
reduced dyspnea after cardiac surgery, whereby an inflammatory response is considered an underlying 
mechanism.  Intra-thoracic fibrosis from prior surgery may complicate the course of non-specific pleural 
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effusion (e.g. formation of loculations).  Pleurodesis causes fibrosis within the thoracic cavity and may 
change the course of non-specific pleural effusion[53].  Micro-metastatic malignancy is thought to cause 
pleural effusion by a separate process that may promote persistence of pleural effusion[24].  Major 
operative complications, defined as intraoperative bleeding requiring massive transfusion protocol and 
documented injury of intra-thoracic structures, may provoke an immune response beyond that experienced 
by most cardiac surgery patients.  Additionally, we can reasonably assume this would impact length of stay 
and requirement for escalation of care.  Maintenance of an indwelling tunneled pleural catheter has been 
associated with spontaneous pleurodesis[68].  Intraoperative insertion of a chest tube to drain the left 
pleural space has also been shown to reduce pleural effusion after cardiac surgery[69].  INR >2.5 is a 
reference value at the upper standard deviation of increased risk for the development of hemothorax 
requiring transfusion after thoracentesis[70].  From our current interpretation of the literature subclinical, 
bleeding might prolong pleural inflammation and effusion.   
 
5.3 Selection of Cases and Controls 
Query of electronic medical records resulted in a Primary Search Group (PSG) of 377 records for 
consideration amongst patients of Umer M. Darr, MD at Yale - New Haven Hospital during the two-year 
period commencing January 1st, 2013 and ending December 30th, 2014.  Within the PSG, 58 patients had 
undergone thoracentesis.  Manual search of these records yielded 34 patients having had thoracentesis 
during the period of interest (POD3-7).  Of these, 21 patients met the remaining inclusion criteria.  Of those 
meeting inclusion criteria, 4 patients met exclusion criteria on further review due to non-cardiac etiology of 
a chronic pleural effusion (3) or prior sternotomy(1).  The 17 remaining patients were assigned to the 
preliminary Case Group. 
 
Re-generation of the PSG excluding the 58 patients found to have undergone thoracentesis during 
the perioperative period produced 319 patients.  84 patients were identified as age matched by list sort.  
Through manual search, 19 procedure matches were identified amongst matched ages.  These records were 
assigned to the preliminary Control Group. 
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There were 2 additional patients meeting criteria for Cases and 4 additional patients meeting criteria 
to match as Controls to 4 of the first 15 Cases selected.  The 2 additional preliminary Cases were not 
assigned because there was no ability to appropriately age and/or procedure match amongst the available 
Controls.  There were 4 additional Controls that could have been matched to Cases.  We selected those that 
were closest in age as this would be the most reliable comparison.  The Case and Control groups were then 
finalized with the best matches available.  A schematic for Case and Control Selection by numbered step is 
shown in Figure 1. 
 
5.4 Data Abstraction 
Data abstraction was performed by manual search by a medical student and is documented using the 
Data Abstraction Form attached as Appendix A.  Data abstracted was handled per the Data Management 
procedure listed in Section 5.5. 
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Figure 1:  Case and Control Selection 
 
 
5.4.1 Specific Data Elements 
Data elements are retrospectively abstracted from patient charts for the following: 
• Baseline Data 
o Age 
o Cardiac surgical procedure 
• Cardiopulmonary Recovery 
o Daily Peak Supplemental O2 Requirement (LPM), POD3 to discharge (or POD7) 
o Daily Occurrence of AF POD3 to discharge (or POD7) 
o Cumulative dose requirement for amiodarone POD3 to discharge (or POD7)  
o Number of days with fever (e.g. T > 38.3° C) POD3 to discharge (or POD7) 
o Labs: Daily WBC and Platelets (POD3 - POD7, or last lab draw) 
o POD of thoracentesis (Cases) 
Figure 1: Cases and Control selection; 377 patients considered; 58 patients were to found to have undergone 
thoracentesis for non-specific pleural effusion; 41 preliminary Cases were removed by inclusion/exclusion criteria.  2 
preliminary cases were unmatched.  Of 319 potential controls, 84 were age matched and 19 were procedure matched.  
Matching by closest age yielded 15 Cases and 15 Controls  
Legend: 
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o Pleural fluid volume removed (Cases) 
• Postoperative Course 
o Length of post-operative inpatient stay (LOS) 
o Requirement for escalation of care (e.g. Step-down or CTICU re-admission) 
• Post-discharge Course 
o Diagnosis of post-pericardiotomy syndrome 
o Death (< 30-days) 
o Requirement for hospital re-admission 
o Requirement for outpatient management of pleural effusion 
 
5.5 Data Management  
The study is exclusively conducted at Yale University School of Medicine through Yale - New 
Haven Hospital.  Hard copy, de-identified Case Report Forms are used to collect data are secured under 
lock-and-key in a binder within the Section of Cardiac Surgery on completion of Data Abstraction.  All 
electronic media is held in accordance with IRB policies and procedures.  Additionally, de-identified data is 
periodically loaded into Microsoft Excel® and STATA (STATA LP, College Station, TX, USA) for 
analysis and safeguarded on an encrypted hard drive per IRB policies and procedures.  All data records 
used for the study, paper and electronic, will be destroyed on or before a period of 5 years (12/31/2019).   
 
5.6 Data Analysis 
The primary endpoint of this study is frequency of improved dyspnea as measured by daily peak 
supplemental O2 requirement before and after thoracentesis.  The generally accepted criteria for therapeutic 
thoracentesis in our patient population includes symptoms[5].  We have chosen peak supplemental O2 
requirement as a measure of dyspnea for several reasons.  At Yale – New Haven Hospital, the order for 
titration of oxygen supplementation is nursing-driven and is given as: 
Nasal Oxygen Titration (Adult) 
• [Timing], [Duration], [Start Date, Time], [End Date, Time] 
• Starting Liter Flow (LPM):  2.0 LPM 
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• SpO2 Goal:  > or = 92% 
• Indications:  Treat/Prevent Hypoxemia 
• Flow Range:  [Flow Range] 
• Titrate Flow:  [Titration Flow] 
• Notify MD/LIP:  [Any Specific Notification Instructions] 
 
The translated action by nursing staff is most often to supplement oxygen to “prevent hypoxemia.”  
Further, an acceptable interpretation of these orders often results in nurses adding 2L of oxygen for what 
they deem as, “patient comfort.”  This commonly occurs when SpO2 is above 92% to prevent hypoxemia 
in the setting of early increased work of breathing.  The initial flow typically given is also in accordance 
with physician orders, which is 2 LPM.  Oxygen is titrated up based on a combination of increased work of 
breathing and trending of hypoxia by SpO2.  The peak oxygen supplementation that is the end result of 
titration is probably a good measure of exactly how much dyspnea someone is experiencing prior to 
changes in supplementation. 
 
Does everyone get 2 LPM of oxygen when they’re experiencing some increased work of breathing?  
This is also probably not the case.  The subjectivity of a nurses’ assessment of increased work of breathing 
may be influenced by, among factors, recent thoracentesis.  If a thoracentesis has been performed, there 
might be an expectation that someone will get better.  This could be an influence for a nurse to titrate less 
aggressively if there is a subjective expectation.  The measure of SpO2 has been used in prior studies to 
measure hypoxia in patients before and after thoracentesis[65].  We considered using this measure, 
however, many patients requiring cardiac surgery have chronic obstructive pulmonary disease.  It is 
common for these patients to have a low baseline SpO2 without significant changes in baseline work of 
breathing.  If a patient’s work of breathing isn’t dramatically changed, this may result in less aggressive 
initiation of oxygen supplementation by nurses if the SpO2 is > 92%.  Lastly, it is rare at our institution for 
someone to have an SpO2 < 92% at the time of surgeon orders for thoracentesis.  This result is primarily a 
function of the physician order set for oxygen titration.  For these considerations, we are choosing to use 
daily peak O2 supplementation as a measure of dyspnea.  Further, we think that a relevant measurable 
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difference is 2 LPM because the oxygen titration starts at a 2 LPM by our order set.  Although this has 
never been measured and is not dictated by the order set, our practitioners report that most patients are 
titrated off oxygen from 2 LPM.  We would therefore consider “improved dyspnea” by a reduction of 2 
LPM. 
 
We feel POD3 - POD7 is a reasonable inpatient study period for several reasons.  Patients at our 
institution are admitted to the CT-ICU following open cardiac surgery. On approximately POD 1-3, 
patients’ chest tubes are typically removed and they are transferred to the CT-SDU.  Following 24-48 hours 
in CT-SDU, patients are transferred to the Cardiovascular Medical Floor (CMF) where they typically 
remain until discharge.  Thoracentesis for non-specific pleural effusion occurs after chest tubes are 
removed (usually POD2).  The literature suggests that non-specific pleural effusions resolve within 1 week 
of surgery (POD7)[5].  Therefore, we choose these as the limits of data to examine. 
 
The secondary endpoint is hospital length of stay (LOS); which is defined as period of time 
commencing with the day of the primary operation and ending the day of discharge. A mean difference in 
hospital stay for patients of at least 1 day is considered meaningful because inpatient hospital stay is 
recorded by the day in our EMR.  Patients are recorded as discharged based on the date of the hospital 
discharge summary.  Therefore, there is no difference recorded if a patient is discharged before or after 
11:00 AM (the official time of discharge set by hospital administration for billing purposes).  Mid-level 
practitioners estimate that the average hospital LOS for patient at our institution is typically 5-6 days, 
although this has not been formally measured.  The literature suggests that patients with symptomatic 
pleural effusion after cardiac surgery stay 9-10 days after thoracentesis, and 12-13 days if diuretics are used 
as an intervention[65].     
 
The tertiary endpoint is requirement for escalation of care.  This is defined as the physical relocation 
of a patient to another Unit where the intensity of care is higher due to clinical need.  Our Cardiac Surgery 
service accepts a rate of escalation of care of ≤10%.  In the rare case that a patient is not transferred from 
the CT-SDU to the CMF due to bed management issues, and documentation of an adverse change in 
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clinical course is present in the patient Discharge Summary, the patient were recorded a having had an 
escalation of care. 
 
Additional outcome endpoints include days of documented atrial fibrillation; a requirement for 
outpatient thoracentesis for pleural effusion after discharge; evidence of systemic inflammation [e.g. WBC, 
Fever, platelets]; incidence of post-pericardiotomy syndrome; average hospital length of stay from 
intervention to discharge; amount of pleural fluid removed during thoracentesis; 30-day and absolute 
mortality. 
 
Statistical analysis of study data is accomplished in STATA/IC 10.1 (Stata Corporation, 4905 
Lakeway Dr., College Station, TX 77845 USA) using the Do-Command Program, written by the medical 
student (David R. Kull, MPH) and attached hereto as Appendix B. 
 
5.7 Statistical Considerations 
The primary endpoint of this study is frequency of improved dyspnea as measured by daily peak 
supplemental O2 requirement before and after thoracentesis.  Our study objectives are to review enough 
patient records sufficient to provide for both the statistical power required to be reasonably confident in the 
measurement of our primary and tertiary endpoints.  Additionally, we would like to detect meaningful 
differences between Case and Control groups for the secondary endpoints.  We will not purposefully power 
the study to detect differences in other endpoints. 
 
A sample size of 30 (n) is chosen (Cases=15, Controls=15) based on the following considerations: 
Primary Endpoint:  The primary endpoint of this study is frequency of improved dyspnea.  This 
is defined by a reduction in daily peak O2 supplementation of 2 LPM after thoracentesis.  We 
conservatively estimate that the majority of patients (>50%) have improved dyspnea after 
thoracentesis.  In order to be reasonably confident in our actual rate being above 50%, we would 
need to observe rates that differ by the number of patients: 
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Observed Rate (%) Actual Rate (%) Confidence (%) Patients (n) 
60 50 95 152 
70 50 95 36 
80 50 95 15 
90 50 95 7 
70 50 90 26 
80 50 90 11 
 
Statistical estimates can be made for the magnitude of difference in means for daily peak O2 
supplementation before and after thoracentesis.  We estimate that the average thoracentesis patient 
in our population requires daily peak O2 supplementation of about 4 LPM (+/- 2 LPM) to maintain 
SpO2 above 92%, although this has not been formally measured.  A minimum post-thoracentesis 
value would be 2 LPM (+/-2) based on our definition of “improved dyspnea.”  To detect this 
difference where α = 0.05 and β = 0.20, a minimum of 12 patient records must be analyzed (n=12). 
 
We expect that patients who do not have thoracentesis will also have improved dyspnea, as non-
specific pleural effusion is known to resolve spontaneously[5].  The perioperative day-to-day 
course of spontaneous dyspnea improvement [e.g. when and how much] in this population has not 
been described.  We believe that the majority of patients will have improved dyspnea after 
thoracentesis independent of the POD of intervention.  However, the proportion of patients with 
spontaneous improvement is presumed to be higher in the early versus later perioperative course 
[e.g. POD dependent].  Therefore, we will measure and compare differences in improvement of 
dyspnea for Cases and Controls but we do not yet have enough information to formally power the 
study to detect these differences. 
 
Secondary Endpoint:  Our secondary endpoint is hospital length of stay measured in days.  The 
average hospital stay for patients following cardiac surgery is approximately 5 days (+/- 1-day).  A 
mean difference in hospital stay for patients of at least 1 day is considered meaningful because 
inpatient hospital stay is typically recorded and billed by the day.  The mean hospital length of stay 
will be calculated based on collected data and a paired t-test will be performed.  Assuming that the 
average length of stay is 5 days with a standard deviation of 1 day, and an average mean difference 
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in length of stay is 4 days with a standard deviation of 1 day where α = 0.05 and β = 0.20, a 
minimum of 12 patient records per group must be analyzed (n=24). 
 
Tertiary Endpoint:  The tertiary endpoint of our study is requirement for escalation of care as 
measured by physical transfer to a unit where the intensity of care is higher.  We have units for 
three levels of care at Yale New Haven Hospital [e.g. Cardiovascular Medical Floor, 
Cardiothoracic Step Down, and CTICU] and therefore our definitions and thresholds for transfer 
may be specific to our institution.  Estimates of escalation of care available in the current literature 
are therefore difficult to generalize for our institution.  However, the rate of escalation of care for 
postoperative cardiac surgery patients ranges from approximately 4-13% based on hemodynamic 
instability and the rate of iatrogenic injury from thoracentesis requiring intervention is between 0-
6%[63, 67].  At our institution, a clinically acceptable rate of escalation of care will be defined as 
≤10%.  The rate of escalation of care in our population has not yet been defined.  No comparison 
will be made for escalation of care between Cases and Controls.  However, the rates of escalation 
of care will be calculated for each group and confidence intervals will be calculated using 
Newcombe’s interval (with continuity correction).  The Probability (P) of observing the rates of 
complications for our analysis based on an acceptable comparison rate of ≤10% (p) will be 
calculated by binomial expansion.  We accept that at one patient in ten will have required an 
escalation of care.  To be 80% confident (P) that our rate is ≤10%, the observed rate in our study 
must be 7% per group.  A sample size of 15 per group (n=30) will allow us to detect an observed 
rate of 7% [e.g. 1 event amongst 15 patients] with 80% confidence that our actual rate is ≤10%. 
 
The minimum sample size for our study is n=30 (15 Cases, 15 Controls), which is driven by two 
requirements.  First, we would like higher confidence in our primary endpoint because the estimation of our 
actual rate is conservatively low (>50%).  Our mid-level providers assert that our recent rate of improved 
dyspnea is 90-100%.  We think that a 15-patient Case group provides us with sufficient patients for 95% 
confidence if our observed rate is 80%.  The second requirement is reasonable confidence (80%) in our rate 
of escalation of care being ≤10%.  We think that 80% confidence is reasonable given that this is a pilot 
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study and this rate has never been measured.  The sample sizes required for the primary and secondary 
endpoints are lower based on the best available estimates of absolute differences expected between Cases 
and Controls. 
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6 Results 
6.1 Baseline Patient Characteristics 
Of patients studied, 20 underwent CABG, 6 underwent aortic valve repair (AVR), and 4 underwent 
CABG with AVR as shown in Table 2.  The mean age of the Case group was 75.3 years (SD = 8.2) versus 
74.9 years (SD = 8.1); (p = 0.89).   
 
6.2 Primary Endpoint:  Frequency of Improved Dyspnea 
The primary endpoint of this study is frequency of improved dyspnea as measured by daily peak 
supplemental O2 requirement before and after thoracentesis.  All patients maintained a pleural effusion on 
POD3 during the study period irrespective of Case or Control status.  Of 15 Cases, 11 had decreased peak 
supplemental oxygen requirement ≥2 LPM the day after thoracentesis (RR=0.73, 95% CI 0.45 – 0.92).  Of 
the remaining Case patients, 2 patients had no change in dyspnea and 2 had worsening of dyspnea (≥2 LPM 
increase).  Additionally, 7 of 15 matched Control patients also experienced improved dyspnea over the 
equivalent postoperative period.  We did not detect a significant difference in the odds of improved dyspnea 
between Cases and matched Controls (OR = 3.1, p = 0.14, 95% CI 0.7 – 14.5) or any other change in 
dyspnea (p = 0.79).  These results are shown in Table 2. 
 
The day of thoracentesis ranged from POD3-POD5.  The frequency of thoracentesis on POD3, 4, 
and 5 was respectively 5, 6, and 4.  Mean daily peak supplemental O2 requirement the day following 
thoracentesis for Cases was significantly lower than the day before thoracentesis (1.7 versus 3.3 LPM, p = 
0.01).  The mean daily peak O2 requirement during the equivalent period for matched Controls was also 
significantly lower over the same period (0.4 versus 1.7 LPM, p = 0.01).  There was no relationship 
between the volumes of pleural fluid removed and improved dyspnea by logistic regression analysis (p = 
0.59). 
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Figure 2:  Postoperative Changes in Dyspnea Amongst Cases and Controls 
 






















6.3 Secondary Endpoint:  Postoperative Length of Stay 
Study patients accounted for 188 days of postoperative hospital stay.  The total postoperative days 
experienced by cardiac surgery patients who had thoracentesis for non-specific pleural effusion were 101 
days versus 87 days by those who did not have procedural intervention.  The mean postoperative LOS for 
Cases was 6.7 ± 3.2 days (median = 6) versus 5.8 days ± 1.6 days (median = 5) for Controls (p=0.84).  The 
mean length of stay from intervention to discharge for Cases was 2.8 ± 2.7 days and was not significantly 
different versus the equivalent Control day to discharge, 1.9 ± 1.8 days (p = 0.84).  Regression analysis 
revealed a significant relationship between the volumes of pleural fluid removed during thoracentesis and 
length of stay (Coef = 90 mL/day, p = 0.03).   
 
  
Figure 2: A. Primary Endpoint: Frequency of improved dyspnea in cardiac surgery patients with non-specific pleural 
effusion after thoracentesis (Cases) or a matched period (Controls), as measured by ≥2 LPM reduction in daily peak O2 
supplementation.  Of 15 Cases, 11 patients had improvement in dyspnea, and of 15 Controls, 7 patients had improvement.  
There was no significant difference in the odds of improved dyspnea between Cases and matched Controls (OR = 3.1, p = 
0.14).  B.  Daily peak O2 requirement was significantly lower for Cases after thoracentesis (1.7 versus 3.3 LPM, p = 
0.01).  The difference was also significantly lower over the same period for Controls (0.4 versus 3.7 LPM, p = 0.01).** 
 
** Significance determined by paired t-test; which is independent of 95% confidence interval overlap in Figure 2B.  
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Figure 3: Postoperative Length of Stay Amongst Cases and Controls 
 


















6.4 Tertiary Endpoint:  Requirement for Escalation of Care 
During this study, there was no requirement for escalation of care documented amongst cardiac 
surgery patients with non-specific pleural effusion.  The 95% confidence interval for the rate of escalation 
of care is 0% –14% based on an observed rate of 0% in 15 patient groups. 
 
  
Figure 3: A.  Secondary Endpoint: The postoperative LOS for cardiac surgery patients who had 
thoracentesis was 6.7 days ± 3.2 (median = 6) versus 5.8 days ± 1.6 (median = 5) for those with non-
specific pleural effusion who did have procedural intervention (p=0.84).  B.  Larger requirement for pleural 
fluid removal significantly correlated with Case length of stay (Coef = 90 mL/day, p = 0.03). 
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n = 15 n = 15 
      Mean (SD) Mean (SD) (p) 95% CI 
Baseline Data 
    
Age Age 75. 3 (8.2) 74.9 (8.1) 0.89  
Procedure CABG 10 10   
  Aortic Valve Repair (AVR) 3 3   
  CABG + AVR 2 2   
Dyspnea       
  Improved 11 7 0.14  
  No Change 2 7   
  Worsened 2 1   
 Pre-/Post- Thoracentesis (or 
matched period) Difference 
for Daily Peak O2 
Requirement (LPM) 
-3.2¥ (4.6) -2.3¥ (4.2) 0.36 -3.6 – 2.6 
 Median Pleural Fluid 
Drained 0.5 L    
Postoperative LOS     
  Total Days 101 87   
  Average Days 6.7 (3.2) 5.8 (1.6) 0.84  
  Thoracentesis (or 
Matched POD) to 
Discharge 
2.8 (2.7) 1.9 (1.8) 0.84  
Requirement for Escalation of Care     





6.5 Other Endpoints 
6.5.1 Requirement for Post-Discharge Care of Pleural Effusion 
The requirement for post-discharge outpatient management of pleural effusion was equal, 7% for 
Cases who had thoracentesis and 7% for Controls who did not have procedural intervention (95% CI 0.00-
0.34).  The requirement for readmission was equal, 13% for both Cases and Controls (95% CI 0.02-0.42).  
Table 2:  Comparison of Cases who underwent thoracentesis versus age and procedure matched Controls who had no 
procedural intervention for non-specific pleural effusion after cardiac surgery.  Age was not significantly different between 
Cases and Controls (75.3 vs. 74.9 years, p=0.89).  There is no significant difference for improvement of dyspnea between 
Cases and Controls (11 vs. 7 patients, OR = 3.1, p = 0.14).  Length of stay (LOS) was not significantly different between Case 
and Control Groups (6.7 vs. 3.2 d, p = 0.84).  LOS after thoracentesis (or matched POD) was also not significantly different 
between Cases and Controls.  There was no requirement for escalation of care in either group (95% CI 0.00 – 0.14). 
 
¥ Reported as difference in means, consistent with the appropriate paired t-test.  This is not as group mean 
* Confidence interval is estimated for actual rate of escalation of care, based on an observed rate of 0% in 15 patient groups. 
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6.5.2 Incidence of Atrial Fibrillation 
A total of 11 patients with pleural effusion experienced at least one postoperative day of AF 
following cardiac surgery from POD3-POD7 (RR = 0.37, 95% CI 0.21 – 0.56).  There was no significant 
difference between Cases and Controls for the incidence of postoperative AF (3 versus 8 patients, OR = 
0.22, p = 0.13).  Cases experienced postoperative AF for a mean of 2.3 days (SD = 1.5) and Controls 
experienced a mean of 1.8 days, (SD = 0.7) (p=0.45) as shown in Table 3.  Where thoracentesis was 
performed before POD5 (n = 11), there was no incidence of AF in Case patients.  This was significantly 
lower compared to 6 of 11 Control patients who experienced AF as shown in Table 4 (p = 0.01).   
 
There was no significant difference in the mean daily dose of amiodarone between Cases and 
Controls during postoperative stay, 670 ± 1070 mg versus 730 ± 1070 mg, (p = 0.43).  Cases required 
significantly less amiodarone than Controls if thoracentesis was performed before POD5 (n = 10), 220mg ± 
520 versus 930mg ± 1190, (p=0.01).  Postoperative AF had resolved by discharge for Cases, however, 1 
Control patient was in AF on the day of discharge. 
 
6.5.3 Incidence of Post-pericardiotomy Syndrome 
During this study, there was no incidence of post-pericardiotomy syndrome documented amongst 
cardiac surgery patients with non-specific pleural effusion. 
 
6.5.4 Evidence for Systemic Inflammation 
During the inpatient study period, there was no significant difference in daily WBC for cardiac 
surgery patients who had thoracentesis for pleural effusion versus who did not have procedural 
intervention.  Mean WBC during the inpatient study period was 9.8 ± 0.7 for Cases versus 9.9 ± 0.9 for 
Controls (p = 0.46).  Mean WBC the day after thoracenteses was 7.1 ± 5.1 for Cases versus 7.2 ± 5.4 X 103 
cells/mL for Controls on the equivalent POD (p=0.48).  There were no fevers reported for Case or Controls 
during the study.  The mean platelet count the day after thoracentesis was 139 ± 94 for Case and 151 ± 108 
X 103 cells/mL for Controls on the equivalent POD (p = 0.37).   
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6.5.5 30-day Mortality 
There was neither 30-day mortality nor absolute mortality documented amongst cardiac surgery 
patients with non-specific pleural effusion during this study. 
 
6.5.6 Pleural Fluid Volumes Evacuated (Cases) 
The median volume of pleural fluid removed from Case patients was 0.50 ± 0.50 L (Range 0.08 – 
1.96L) 
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Table 3:  Comparison of Cases and Controls:  Incidence of Atrial Fibrillation 
 
 Cases Controls   
  n = 15 n = 15     
  Mean (SD) Mean (SD) (p) 95% CI 
Atrial Fibrillation (AF)         
  Total Patients with AF 3 8 0.13#   
  Mean Days AF 2.3 (1.5) 1.8 (0.7) 0.45   
  Cum. Dose Amiodarone 670 (1070) 730 (1070) 0.43   
  Patients Discharged in AF 0 1 0.32   
Sensitivity Analysis by POD     
AF in Patients where 
Thoracentesis < POD5 (n = 11)  0 6 0.01
#   
	  	   Cum. Dose 
Amiodarone 220 (520) 930 (1190) 0.01   
Evidence of Systemic Inflammation         
WBC Mean 9.8 (0.7) 9.9 (0.9) 0.46   
  
Day after 
Thoracentesis 7.1 (5.1) 7.2 (5.2) 0.48   
(or Matched POD) 
Fever Days (T > 38.3°C) 0 0 0.5   
Platelets 
Mean on Day after 
Thoracentesis (or 
Matched POD) 
139 (94) 151 (108) 0.37   
Mortality           
  30-day 0 0 	  	   0.00 - 0.14* 






Table 3:  Comparison of Cases who underwent thoracentesis versus age and procedure matched Controls who had no procedural 
intervention for non-specific pleural effusion after cardiac surgery.  There was no significant difference in the study incidence of AF 
between Cases and Controls (3 vs. 8 patients, p = 0.13).  The mean number of days in AF for individual patients was approximately 
2 days and was not significantly different between groups (p = 0.45).  Cases who underwent thoracentesis earlier than POD5 (n = 
10) had no postoperative atrial fibrillation.  This was significantly lower compared to 6 Control patients who had AF (p = 0.01).  The 
cumulative dosing of amiodarone was significantly lower in Case patients when thoracentesis was performed <POD5 (n = 10, 220 
vs. 930 mg, p = 0.01).  There were no significant differences in markers of systemic inflammation including WBC (p = 0.46), fever 
(p = 0.5), or platelet counts (p = 0.37).  No patients died during the inpatient or outpatient study periods in this study.  The estimated 
95% CI based on the study observation of death is 0 –14%. 
 
# Determined by two – tailed Fisher’s Exact Test 
* Confidence interval is estimated for actual rate of mortality, based on an observed rate of 0% in 15 patient groups. 
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Table 4:  Comparison of Cases who underwent thoracentesis versus age and procedure matched Controls who had no procedural 
intervention for non-specific pleural effusion after cardiac surgery.  Amongst Cases and Controls, there was no difference in the 
overall number of days of AF (2.3 ± 1.5 vs. 1.8 ± 0.7, p=0.45), or daily incidence of AF (OR = 0.22, p = 0.13).  Where 
thoracentesis was performed before POD5 (n = 10), there was no incidence of AF in Case patients versus 6 of 10 Control patients 
(OR = 0, p = 0.01).  There was no significant difference in the mean daily dose of amiodarone between Cases and Controls during 























5 81 CABG + AVR
5 71 CABG
POD3-4 Match 81 CABG
POD3-4 Match 85 CABG
POD3-4 Match 80 CABG
POD3-4 Match 69 CABG
POD3-4 Match 84 AVR
POD3-4 Match 76 CABG
POD3-4 Match 75 AVR
POD3-4 Match 79 CABG+AVR
POD3-4 Match 66 CABG
POD3-4 Match 62 CABG
POD3-4 Match 75 CABG
POD5 Match 80 CABG + AVR
POD5 Match 70 CABG
POD5 Match 59 CABG
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7 Discussion 
Non-specific pleural effusion contributes to pulmonary dysfunction after cardiac surgery[4, 8-10].  
In the present study, our objectives were to 1) measure the frequency of reduced dyspnea after thoracentesis 
on cardiac surgery patients with non-specific pleural effusion; and 2) compare clinical outcomes between 
patients who had thoracentesis versus those who did not have procedural intervention.  To our knowledge, 
this is the first comparative evaluation of outcomes for early thoracentesis in cardiac surgery patients with 
non-specific pleural effusion. 
 
The observed frequency of improved dyspnea after thoracentesis was 73% as measured by a ≥2 
LPM reduction in daily peak supplemental O2 requirement.  Although the limited sample size does not 
allow this rate to be defined precisely, we are reasonably confident that the majority of patients improve 
after intervention is performed (95% CI 0.45 – 0.92).  The median volume of pleural fluid removed from 
Case patients was 0.50 ± 0.50 L (Range 0.08 – 1.96L).  There was no relationship between the volumes of 
pleural fluid removed and improved dyspnea in our study (p = 0.59).  The median pleural fluid volume 
removed from patients by thoracentesis in our study generally correlates with blunting of the costophrenic 
angles on a chest radiograph[65].  This volume is also at the intervention cut off point in the algorithm 
proposed by Usta, et al for symptomatic patients[65]. 
 
We have proposed that non-specific pleural effusion after cardiac surgery is the result of interrelated 
lung and pleural inflammation; and early reduction of PMN burden in the pleural space with thoracentesis 
might shorten the duration of symptoms.  Most non-specific pleural effusions are thought to spontaneously 
resolve about a week after uncomplicated cardiac surgery[5].  Whether or not thoracentesis improves 
dyspnea beyond that which is experienced during the typical day – to – day postoperative course is unclear. 
The odds ratio for improvement of dyspnea for Cases who had thoracentesis versus age and operation 
matched Controls was 3.1.  But this was not significant for the limited number of patients studied (p = 0.14, 
95% CI 0.7 – 14.5).  
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One interpretation of this result could be that thoracentesis doesn’t improve dyspnea compared to the 
typical day – to – day postoperative course.  For this interpretation, we would offer that reduction of PMN 
burden had no impact on dyspnea.  Symptomatic improvement after thoracentesis is generally correlated 
with increasing volumes of pleural fluid removed[11, 12].  If there is no difference between these groups, 
we might explain this by the small size of effusions encountered (median = 0.5 L).  However, an alternative 
explanation is that the current study was underpowered to detect significant differences between the two 
groups.  The upper limit of the OR 95% confidence interval is 14.5 in the setting of a trend toward 
statistical significance.  This large upper limit leads us to believe that the study was in fact, underpowered 
to detect a significant difference.  
 
We found no significant difference in LOS for Cases who had thoracentesis versus Controls who did 
not (6.7 ± 3.2 days versus 5.8 ± 1.6 days, p=0.84).  Therefore, we could not substantiate reports made by 
mid-level providers that cardiac surgery patients experience fewer postoperative days in hospital after 
thoracentesis.  Patient LOS at our institution was observed to be shorter than for similar patients in the 
literature (5-7 versus 9-14 days)[64]. 
 
An interesting related observation is that Cases who required thoracentesis had a significantly higher 
oxygen requirement on POD3 versus matched Controls (mean = 2.7 versus 1.2 LPM, p = 0.02).  If patients 
who had thoracentesis were more symptomatic than matched Controls, but there was no difference in LOS, 
this raises some questions about the role of thoracentesis in their course of recovery.  The mean length of 
stay from thoracentesis to discharge for Cases was not significantly different versus the equivalent day to 
discharge for Controls (2.8 vs. 1.9 days, p = 0.84).  Linear regression analysis revealed a significant 
positive correlation between LOS and POD of thoracentesis (Coef. of Variation = 2.5, SE = 0.84, p < 0.01).  
By this trend, we could predict that patients who had thoracentesis on POD3 would stay 4 days, on POD4 
would stay 7 days, and POD5 would stay 9 days.  Although we cannot say whether or not thoracentesis 
augmented hospital course, there is an argument that this might have been the case. 
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We did not observe escalation of care during the study period for either Cases or Controls.  Based on 
our statistical analysis, the probability that our actual rate of escalation of care is ≤10% can be made with 
>95% confidence (p = 0.04, 95% CI 0.00 – 0.14).  Although not explicitly an endpoint, there were no 
complications of bleeding, infection, or pneumothorax attributable to thoracentesis during the study. 
 
Approximately 30% of inpatient cardiac surgery patients will have postoperative AF[67].  The 
current study observed a rate of 33% amongst all patients, which is consistent with the literature.  There 
was no significant difference between Cases and Controls for the odds of developing postoperative AF 
during the present study (3 versus 8 patients, OR = 0.22, p = 0.13).  If a patient had postoperative AF, the 
mean number of days in AF was also not significantly different between Case and Control patients (2.3 
versus 1.8 days, p = 0.45).  Sensitivity analysis by the POD of thoracentesis demonstrated that the odds of 
postoperative AF were significantly reduced for Cases (0:11) versus matched Controls (6:5) if intervention 
was performed before POD5 (p = 0.01).   The incidence of AF was also significantly lower for Cases who 
underwent thoracentesis prior to POD5 (0 of 11 patients) versus Cases who underwent thoracentesis on 
POD5 (3 of 4 patients)(95% CI 0.00 – 0.95, p = 0.05).  
 
The differences in incidence of postoperative AF amongst Cases and Controls might be explained by 
several factors.  These include: 1) inpatient medical management, 2) systemic inflammation, 3) 
postoperative risk factors, 4) preoperative risk factors, and 5) the study design [e.g. resolution of AF prior 
to POD3].  First, the cumulative dosage of amiodarone was not significantly different between groups 
during the inpatient period of study (670 versus 730 mg, p = 0.43).  Second, there was no difference 
observed for markers of systemic inflammation during the study.  These included mean WBC (9.8 vs. 9.9 X 
103 cells/mL, p < 0.46) and the absence of fever during the inpatient period of study in both groups.  Third, 
the highest postoperative risk factors for new onset AF after cardiac surgery are pulmonary edema (OR = 
5) and pleural effusion requiring thoracentesis (OR = 3)[59].  Although not formally measured, nearly all of 
the Cases and Controls had some minor component of pulmonary edema on their POD3 chest x-ray.  By 
design, only Cases had been determined to require a thoracentesis during the study.  We did not find an 
increased risk of postoperative AF with the requirement for thoracentesis. 
Page 51 of 67 
  
 
Fourth, the highest preoperative risk factor for postoperative AF is a prior history of AF[67].  
Although the incidence of AF [e.g. chronic or paroxysmal] in the general population is 2 – 4%, the 
incidence of preoperative AF for patients undergoing cardiac surgical procedures is approximately 
30%[67].  Contributing preoperative risk factors for new onset of postoperative AF include age >75 years 
and history of stroke[59, 67].  The mean age of patients in our study was 75 years but this was not different 
between Case and Control groups (p = 0.89).  However, we did not evaluate prior history of AF or stroke to 
account for differences in the risk of postoperative AF.  Perhaps preoperative risk might explain the 
differences in both incidence and persistence of AF between the two groups after cardiac surgery.  Fifth, 
additional reasons for not detecting postoperative AF would have been resolution prior to POD3 or 
occurrence after POD7. 
 
An alternative explanation for the differences in incidence of AF between Cases and Controls is the 
early treatment of pleural effusion.  Stamou, et al, have shown that pleural effusion is a risk factor for new 
onset AF after cardiac surgery[59].  Pericardial effusion is also a known risk factor for AF and up to 63% 
of patients maintain a sub-clinical pericardial effusion 1-week after surgery[60].  Vargas, et al, have 
demonstrated that the persistence of pericardial effusion is dependent on the persistence of pleural effusion 
after myocardial revascularization[61].  Early treatment of pleural effusion in Cases might therefore explain 
the difference in incidence of AF.  We have also proposed that early reduction of PMN burden in the 
pleural space with thoracentesis might shorten the duration of lung and pleural inflammation.  The COPPS-
2 trial demonstrated a lower incidence of both pleural effusion and atrial fibrillation with the use colchicine 
as an anti-inflammatory agent[57].  One of the mechanisms of action for colchicine is reduction in PMN 
recruitment[57].  It is reasonable to suspect that reducing PMN recruitment with colchicine would have 
reduced PMN burden in the pleural space.  Although not definitive, the present study might provide some 
evidence that PMN burden in the pleural space is part of the pathogenesis pathway in postoperative AF.   
 
There are several limitations to this study.  First, daily peak O2 supplementation was used as a 
surrogate marker of changes in dyspnea in the absence of a validated instrument.  A validated instrument 
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would have presumably produced more precise results.  Second, a small number of patients were thought 
required to show statistical significance in terms of the major endpoints for this study.  We did not power 
the study appropriately to show differences for our other endpoints and this was a limitation to interpreting 
some of the results.  Third, our findings for postoperative AF are interpreted with some hesitation.  We did 
not evaluate patients for preoperative risk factors for postoperative AF.  Preoperative risk could have 
explained the differences in both incidence and persistence of AF during the study.  Lastly, our study 
design was useful in terms of expeditiously completing a low-cost pilot project but the results might not be 
readily generalizable to larger populations of cardiac surgery patients.    
 
Several research questions that have emerged from the present study.  First, who is appropriate for 
thoracentesis after cardiac surgery?  Usta, et al, used the size of pleural effusion (> 480mL) estimated by 
chest x-ray and thoracic ultrasound in symptomatic patients in order to determine who should undergo 
thoracentesis[65].  For smaller symptomatic effusions, patients in their study received diuretics[65].  In our 
study, more than half the Cases that improved after thoracentesis had a pleural fluid volume of less than 
400mL.  Additionally, there is no comparative data to suggest that diuretics are a superior therapy to 
thoracentesis for patients with smaller effusions.  Diuretics increase the concentration of proteins in the 
pleural space as compared to thoracentesis[71].  This could feasibly promote ongoing inflammation and 
related pulmonary symptoms after cardiac surgery.  Usta’s study also suggests that LOS is longer for 
patients who receive diuretics for small effusions[65].  Perhaps the use of diuretics in these small effusions 
evolved due to the historically poor complication rate for thoracentesis in the setting of uncertain benefit.  
If this is the case, its use in smaller effusions might require some reconsideration given the reduced 
complication rate for thoracentesis with thoracic ultrasound. 
 
Second, does thoracentesis augment the postoperative course of patients with non-specific pleural 
effusion who require intervention after cardiac surgery?  We think that the current report lays some 
groundwork for such an outcomes study.  The goals of our study were to measure frequency of 
improvement and compare selected outcomes with age and procedure controls.  We found that the majority 
of patients experience some improvement of dyspnea with thoracentesis but these people might have been 
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sicker after surgery.  We have further demonstrated that there are increased odds for improved dyspnea for 
patients who have thoracentesis versus age and operation matched controls.  We did not show significance 
for this result, likely because the study was not powered to detect it.  We have reported that there is no 
difference for LOS between patients who have thoracentesis.  A larger study might have also detected a 
difference for LOS that favored Controls.  Lastly, regression analysis suggested that patients who had 
thoracentesis later in their course, stayed longer.  We think that there might be a beneficial impact for 
thoracentesis in the postoperative course for certain patients who require intervention.  But this has yet to 
be fully elucidated. 
 
Lastly, is there a role for early thoracentesis (before POD5) in reducing postoperative AF?  
Designing an ideal study with generalizable results might be challenging at this point.  We can, however, 
offer some considerations based on the learning from our current study.  First, a prospective study might 
enable the use of an instrument that reliably documents preoperative risk factors for postoperative AF.  Our 
current study would have benefited from an accurate account of preoperative risk factors for AF in 
interpreting our results.  Second, we might consider broadening the inpatient period of study to encompass 
the entire postoperative length of stay.  We did not measure postoperative AF prior to POD3 or after POD7 
in the current study, which may have biased our results.  Third and as suggested above, a better 
understanding of which patients should have intervention might be helpful in determining selection criteria 
for an intervention group in a prospective study.  Well-defined selection criteria might help determine the 
limits of generalizability for reported results.  In the current study, it was unclear what the selection criteria 
were for thoracentesis and this impacts the generalizability of our reported outcomes data. 
 
8 Conclusions 
The present pilot study suggests that the majority of patients who have symptomatic pleural effusion 
have some improvement in dyspnea after thoracentesis.  This benefit did not translate into reduced length 
of stay.  Our observations also suggest that patients might experience fewer days in AF with thoracentesis, 
particularly if performed earlier in the course of their postoperative care.  These observations were limited 
to patients with pulmonary symptoms that required thoracentesis based on unclear clinical criteria.  We 
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interpret these results with some hesitation, primarily because preoperative risk factors for postoperative 
AF could have explained differences detected between Cases and Controls.  Future research might focus on 
better defining the clinical criteria for thoracentesis in non-specific pleural effusion and better 
understanding the impact of intervention on postoperative course. 
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10 Appendix A 
10.1 Data Abstraction Form 
Perioperative Intervention for Post-pericardiotomy Pleural Effusion 
 
Unique Identifier: _________________________  
10.1.1 Baseline Data and Assessment 
 
1. Patient meets all criteria for study inclusion: ☐  Yes (1)                 No (0) 
 
Inclusion Criteria  
Patients with radiographically diagnosed pleural effusion are considered.  Subjects must meet all of 
the following inclusion criteria to be entered into the study:  
• Post-primary open cardiac surgery (CABG, valve, CABG + valve, etc.) 
• Age 40-85 years 
• Diagnosis of postoperative pleural effusion in the perioperative period (< POD7) 
 
2. Patient meets criteria for study exclusion:    Yes (1)                 No (0) 
 
Exclusion Criteria 
Any of the following will exclude the subject from study:  
• Prior cardiac surgery 
• History of pleurodesis 
• Patients with pleural effusion known to be associated with non-surgery related 
etiology (e.g. pancreatitis, malignancy, etc.) 
• Surgical complications (e.g. intraoperative bleeding) 
• Maintenance of a (contralateral) chest tube or Pleurex® catheter at diagnosis of 
pleural effusion 
• INR > 2.5 at the time of thoracentesis 
 
3. Case or Control Subject    Case (1)     Control (0) 
 
4. Case Matched Control Number (if Case) ____________________ 
  
5. Age (years) ____________________ 
  
6. Surgical Procedure o CABG  (0) 
o Valve  (1) 
o CABG + Valve (2) 
o Other  (3) 
If Other, Please Specify: 
______________________________ 
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POD 3 7.  
o 0 L/min (No 
Reqmnt)           (0) 
o > 0, ≤ 2L/min   (1) 
o > 2, ≤ 4L/min   (2) 
o > 4, ≤ 6L/min   (3) 
o > 6, ≤ 8L/min   (4) 
o > 8, ≤ 10L/min (5) 
o > 10L/min        (6) 
 
8.  
o Yes (1) 









o Yes (1) 













POD 4 13.  
o 0 L/min (No 
Reqmnt)           (0) 
o > 0, ≤ 2L/min   (1) 
o > 2, ≤ 4L/min   (2) 
o > 4, ≤ 6L/min   (3) 
o > 6, ≤ 8L/min   (4) 
o > 8, ≤ 10L/min (5) 
o > 10L/min        (6) 
 
14.  
o Yes (1) 










o Yes (1) 













POD 5 19.  
o 0 L/min (No 
Reqmnt)           (0) 
o > 0, ≤ 2L/min   (1) 
o > 2, ≤ 4L/min   (2) 
o > 4, ≤ 6L/min   (3) 
o > 6, ≤ 8L/min   (4) 
o > 8, ≤ 10L/min (5) 
o > 10L/min        (6) 
 
20.  
o Yes (1) 










o Yes (1) 













POD 6 25.  
o 0 L/min (No 
Reqmnt)           (0) 
o > 0, ≤ 2L/min   (1) 
o > 2, ≤ 4L/min   (2) 
o > 4, ≤ 6L/min   (3) 
o > 6, ≤ 8L/min   (4) 
o > 8, ≤ 10L/min (5) 
o > 10L/min        (6) 
 
26.  
o Yes (1) 










o Yes (1) 













POD 7 31.  
o 0 L/min (No 
Reqmnt)           (0) 
o > 0, ≤ 2L/min   (1) 
o > 2, ≤ 4L/min   (2) 
o > 4, ≤ 6L/min   (3) 
o > 6, ≤ 8L/min   (4) 
o > 8, ≤ 10L/min (5) 
o > 10L/min        (6) 
 
32.  
o Yes (1) 










o Yes (1) 













Discharge 37.  
o 0 L/min (No 
Reqmnt)           (0) 
o > 0, ≤ 2L/min   (1) 
o > 2, ≤ 4L/min   (2) 
o > 4, ≤ 6L/min   (3) 
o > 6, ≤ 8L/min   (4) 
o > 8, ≤ 10L/min (5) 
o > 10L/min        (6) 
 
38.  
o Yes (1) 










o Yes (1) 













43. Cases:  POD of Thoracentesis POD:   ________________ 
 
44. Cases:  Pleural Fluid Volume Removed Volume: ________________ mL 
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10.1.3 Postoperative Course 
 
45. Length of Postoperative Inpatient Stay: ________________ Days 
 
46. Requirement for Escalation of Care: q Yes (1) 
q No  (0) 
 
47. Discharge O2 Requirement: ________________ L/min 
       (if none, write 0) 
 
10.1.4 Post-Discharge Course 
 
48. Diagnosis of post-pericardiotomy syndrome: q Yes (1) 
q No  (0) 
 
49. Death (within 30-days): q Yes (1) 
q No  (0) 
 
50. Requirement for hospital re-admission: q Yes (1) 
q No  (0) 
 
51. Requirement for outpatient procedural management of 
pleural effusion: 
q Yes (1) 
q No  (0) 
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11 Appendix B 
11.1 STATA Do-Command Program for Data Analysis 
Study: Thoracentesis in Cardiac Surgery Patients with Non-Specific Pleural Effusion 
Written by David R. Kull, MPH 
* Start Program 
window stopbox rusure "WARNING: The following program 
is designed to run in a specific file structure on one specific 




* System Memory Allocation 
 
set memory 1000000 
 
* Clear Data in Memory and Settings 
clear all 
capture log close 
set more off 
 
* Save Data and Log 
 
log using "/Users/davidkull/Desktop/Pericardiotomy - Pleural 
Effusion MGMT/DATA/ppcpe.log", replace 
 
* Import PPCPE CSV Delimited TXT File 
 
insheet using "/Users/davidkull/Desktop/Pericardiotomy - 
Pleural Effusion MGMT/DATA/PPCPE.csv" 
 
* Label Imported Variables 
 
label var id_case "Case ID" 
label var age_case "Case Age" 
label var proc_case "Case Procedure" 
label var pod2_o2_case "Case POD2 O2 Requirement" 
label var pod3_o2_case "Case POD3 O2 Requirement" 
label var pod3_af_case "Case POD3 Atrial Fibrillation" 
label var pod3_amio_case "Case POD3 Cumulative 
Amiodarone Requirement" 
label var pod3_fev_case "Case POD3 Fever" 
label var pod3_wbc_case "Case POD3 White Cell Count" 
label var pod3_plts_case "Case POD3 Platelets" 
label var pod4_o2_case "Case POD4 O2 Requirement" 
label var pod4_af_case "Case POD4 Atrial Fibrillation" 
label var pod4_amio_case "Case POD4 Cumulative 
Amiodarone Requirement" 
label var pod4_fev_case "Case POD4 Fever" 
label var pod4_wbc_case "Case POD4 White Cell Count" 
label var pod4_plts_case "Case POD4 Platelets" 
label var pod5_o2_case "Case POD5 O2 Requirement" 
label var pod5_af_case "Case POD5 Atrial Fibrillation" 
label var pod5_amio_case "Case POD5 Cumulative 
Amiodarone Requirement" 
label var pod5_fev_case "Case POD5 Fever" 
label var pod5_wbc_case "Case POD5 White Cell Count" 
label var pod5_plts_case "Case POD5 Platelets" 
label var pod6_o2_case "Case POD6 O2 Requirement" 
label var pod6_af_case "Case POD6 Atrial Fibrillation" 
label var pod6_amio_case "Case POD6 Cumulative 
Amiodarone Requirement" 
label var pod6_fev_case "Case POD6 Fever" 
label var pod6_wbc_case "Case POD6 White Cell Count" 
label var pod6_plts_case "Case POD6 Platelets" 
label var pod7_o2_case "Case POD7 O2 Requirement" 
label var pod7_af_case "Case POD7 Atrial Fibrillation" 
label var pod7_amio_case "Case POD7 Cumulative 
Amiodarone Requirement" 
label var pod7_fev_case "Case POD7 Fever" 
label var pod7_wbc_case "Case POD7 White Cell Count" 
label var pod7_plts_case "Case POD7 Platelets" 
label var dis_o2_case "Case Discharge O2 Requirement" 
label var dis_af_case "Case Discharge Atrial Fibrillation" 
label var dis_amio_case "Case Discharge Cumulative 
Amiodarone Requirement" 
label var dis_fev_case "Case Discharge Fever" 
label var dis_wbc_case "Case Discharge White Cell Count" 
label var dis_plts_case "Case Discharge Platelets" 
label var pod_int_case "Case POD Intervention" 
label var case_vol_case "Case Volume Pleural Fluid" 
label var los_case "Case Length of Stay" 
label var escal_case "Case Escalation of Care" 
label var dis_o2req_case "Case Discharged on O2" 
label var ppcs_case "Case Post Pericardiotomy Syndrome" 
label var death_case "Case Death" 
label var readmit_case "Case Readmission" 
label var out_mgmt_case "Case Req for Outpatient 
Management" 
label var id_control "Control ID" 
label var age_control "Control Age" 
label var proc_control "Control Procedure" 
label var pod2_o2_control "Control POD2 O2 Requirement" 
label var pod3_o2_control "Control POD3 O2 Requirement" 
label var pod3_af_control "Control POD3 Atrial Fibrillation" 
label var pod3_amio_control "Control POD3 Cumulative 
Amiodarone Requirement" 
label var pod3_fev_control "Control POD3 Fever" 
label var pod3_wbc_control "Control POD3 White Cell 
Count" 
label var pod3_plts_control "Control POD3 Platelets" 
label var pod4_o2_control "Control POD4 O2 Requirement" 
label var pod4_af_control "Control POD4 Atrial Fibrillation" 
label var pod4_amio_control "Control POD4 Cumulative 
Amiodarone Requirement" 
label var pod4_fev_control "Control POD4 Fever" 
label var pod4_wbc_control "Control POD4 White Cell 
Count" 
label var pod4_plts_control "Control POD4 Platelets" 
label var pod5_o2_control "Control POD5 O2 Requirement" 
label var pod5_af_control "Control POD5 Atrial Fibrillation" 
label var pod5_amio_control "Control POD5 Cumulative 
Amiodarone Requirement" 
label var pod5_fev_control "Control POD5 Fever" 
label var pod5_wbc_control "Control POD5 White Cell 
Count" 
label var pod5_plts_control "Control POD5 Platelets" 
label var pod6_o2_control "Control POD6 O2 Requirement" 
label var pod6_af_control "Control POD6 Atrial Fibrillation" 
label var pod6_amio_control "Control POD6 Cumulative 
Amiodarone Requirement" 
label var pod6_fev_control "Control POD6 Fever" 
label var pod6_wbc_control "Control POD6 White Cell 
Count" 
Page 62 of 67 
  
label var pod6_plts_control "Control POD6 Platelets" 
label var pod7_o2_control "Control POD7 O2 Requirement" 
label var pod7_af_control "Control POD7 Atrial Fibrillation" 
label var pod7_amio_control "Control POD7 Cumulative 
Amiodarone Requirement" 
label var pod7_fev_control "Control POD7 Fever" 
label var pod7_wbc_control "Control POD7 White Cell 
Count" 
label var pod7_plts_control "Control POD7 Platelets" 
label var dis_o2_control "Control Discharge O2 
Requirement" 
label var dis_af_control "Control Discharge Atrial 
Fibrillation" 
label var dis_amio_control "Control Discharge Cumulative 
Amiodarone Requirement" 
label var dis_fev_control "Control Discharge Fever" 
label var dis_wbc_control "Control Discharge White Cell 
Count" 
label var dis_plts_control "Control Discharge Platelets" 
label var pod_int_control "Control POD Intervention" 
label var case_vol_control "Control Volume Pleural Fluid" 
label var los_control "Control Length of Stay" 
label var escal_control "Control Escalation of Care" 
label var dis_o2req_control "Control Discharged on O2" 
label var ppcs_control "Control Post Pericardiotomy 
Syndrome" 
label var death_control "Control Death" 
label var readmit_control "Control Readmission" 
label var out_mgmt_control "Control Req for Outpatient 
Management" 
label var mean_wbc_case "Mean WBC Cases" 
label var mean_wbc_control "Mean WBC Control" 
 
* Label Data from Imported Variables 
 
capture label drop proc_lbl 
label define proc_lbl 0 "CABG" 1 "Valve" 2 
"CABG+VALVE" 3 "Other" 
label values proc_case proc_lbl 
label values proc_control proc_lbl 
 
capture label drop yn_lbl 
label define yn_lbl 0 "No" 1 "Yes" 
 
label values pod3_af_case yn_lbl 
label values pod3_af_control yn_lbl 
label values pod3_fev_case yn_lbl 
label values pod3_fev_control yn_lbl 
 
label values pod4_af_case yn_lbl 
label values pod4_af_control yn_lbl 
label values pod4_fev_case yn_lbl 
label values pod4_fev_control yn_lbl 
 
label values pod5_af_case yn_lbl 
label values pod5_af_control yn_lbl 
label values pod5_fev_case yn_lbl 
label values pod5_fev_control yn_lbl 
 
label values pod6_af_case yn_lbl 
label values pod6_af_control yn_lbl 
label values pod6_fev_case yn_lbl 
label values pod6_fev_control yn_lbl 
 
label values pod7_af_case yn_lbl 
label values pod7_af_control yn_lbl 
label values pod7_fev_case yn_lbl 
label values pod7_fev_control yn_lbl 
 
label values dis_af_case yn_lbl 
label values dis_af_control yn_lbl 
label values dis_fev_case yn_lbl 
label values dis_fev_control yn_lbl 
 
label values escal_case yn_lbl 
label values escal_control yn_lbl 
 
label values ppcs_case yn_lbl 
label values ppcs_control yn_lbl 
 
label values death_case yn_lbl 
label values death_control yn_lbl 
 
label values readmit_case yn_lbl 
label values readmit_control yn_lbl 
 
label values out_mgmt_case yn_lbl 
label values out_mgmt_control yn_lbl 
 
capture label drop o2_lbl 
label define o2_lbl 0 "No O2 Requirement" 1 ">0, <=2 L/min 
O2 Requirement" 2 ">2, <=4 L/min O2 Requirement" 3 ">4, 
<=6 L/min O2 Requirement" 4 ">6, <=8 L/min O2 
Requirement" 5 ">8, <=10 L/min O2 Requirement" 6 ">10 
L/min O2 Requirement" 
 
label values pod3_o2_case o2_lbl 
label values pod4_o2_case o2_lbl 
label values pod5_o2_case o2_lbl 
label values pod6_o2_case o2_lbl 
label values pod7_o2_case o2_lbl 
label values dis_o2_case o2_lbl 
 
label values pod3_o2_control o2_lbl 
label values pod4_o2_control o2_lbl 
label values pod5_o2_control o2_lbl 
label values pod6_o2_control o2_lbl 
label values pod7_o2_control o2_lbl 
label values dis_o2_control o2_lbl 
 
* Generate and Label Pre- post-Intervention Daily Peak O2 
Requirement for Cases 
 
capture drop o2_pre_case 
gen o2_pre_case = 0 
label var o2_pre_case "Case pre-Intervention Peak O2 
Requirement" 
replace o2_pre_case = pod2_o2_case if pod_int_case==3 
replace o2_pre_case = pod3_o2_case if pod_int_case==4 
replace o2_pre_case = pod4_o2_case if pod_int_case==5 
replace o2_pre_case = pod5_o2_case if pod_int_case==6 
replace o2_pre_case = pod6_o2_case if pod_int_case==7 
 
capture drop o2_post_case 
gen o2_post_case = 0 
label var o2_post_case "Case post-Intervention Peak O2 
Requirement" 
replace o2_post_case = pod4_o2_case if pod_int_case==3 
replace o2_post_case = pod5_o2_case if pod_int_case==4 
replace o2_post_case = pod6_o2_case if pod_int_case==5 
replace o2_post_case = pod7_o2_case if pod_int_case==6 
 
capture drop o2_diff_case 
gen o2_diff_case = ((o2_post_case - o2_pre_case)*2) 
label var o2_diff_case "Case Pre-/Post-Int Peak O2 
Supplement Difference" 
 
label values o2_pre_case o2_lbl 
label values o2_post_case o2_lbl 
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capture drop o2_status_case 
gen o2_status_case = 0 
label var o2_status_case "Case Pre-/Post-Int Status Change" 
replace o2_status_case = 0 if (o2_post_case - 
o2_pre_case)==0 
replace o2_status_case = 1 if (o2_post_case - o2_pre_case)<0 
replace o2_status_case = -1 if (o2_post_case - 
o2_pre_case)>0 
label define imp_lbl 0 "No Change" 1 "Improved Dyspnea" -
1 "Worsened Dyspnea" 
label values o2_status_case imp_lbl 
 
capture drop wdyspnea_case 
gen wdyspnea_case = 0 
replace wdyspnea_case = 1 if (o2_post_case - 
o2_pre_case)>0 
label var wdyspnea_case "Worsened Dyspnea" 
 
capture drop ncdyspnea_case 
gen ncdyspnea_case = 0 
replace ncdyspnea_case = 1 if (o2_post_case - 
o2_pre_case)==0 
label var ncdyspnea_case "No Change" 
 
capture drop idyspnea_case 
gen idyspnea_case = 0 
replace idyspnea_case = 1 if (o2_post_case - o2_pre_case)<0 
label var idyspnea_case "Improved Dyspnea" 
 
* Generate and Label Pre- post-Intervention Daily Peak O2 
Requirement for Controls 
 
capture drop o2_pre_control 
gen o2_pre_control = 0 
label var o2_pre_control "Control pre-Intervention Peak O2 
Requirement" 
 
replace o2_pre_control = pod2_o2_control if 
pod_int_control==3 
replace o2_pre_control = pod3_o2_control if 
pod_int_control==4 
replace o2_pre_control = pod4_o2_control if 
pod_int_control==5 
replace o2_pre_control = pod5_o2_control if 
pod_int_control==6 
replace o2_pre_control = pod6_o2_control if 
pod_int_control==7 
 
capture drop o2_post_control 
gen o2_post_control = 0 
label var o2_post_control "Control post-Intervention Peak O2 
Requirement" 
 
replace o2_post_control = pod4_o2_control if 
pod_int_control==3 
replace o2_post_control = pod5_o2_control if 
pod_int_control==4 
replace o2_post_control = pod6_o2_control if 
pod_int_control==5 
replace o2_post_control = pod7_o2_control if 
pod_int_control==6 
 
capture drop o2_diff_control 
gen o2_diff_control = ((o2_post_control - 
o2_pre_control)*2) 
label var o2_diff_control "Control Equiv. Peak O2 
Supplement Difference" 
 
label values o2_pre_control o2_lbl 
label values o2_post_control o2_lbl 
 
capture drop o2_status_control 
gen o2_status_control = 0 
label var o2_status_control "Control Pre-/Post- Equiv. Status 
Change" 
replace o2_status_control = 0 if (o2_post_control - 
o2_pre_control)==0 
replace o2_status_control = 1 if (o2_post_control - 
o2_pre_control)<0 
replace o2_status_control = -1 if (o2_post_control - 
o2_pre_control)>0 
label values o2_status_control imp_lbl 
 
capture drop wdyspnea_control 
gen wdyspnea_control = 0 
replace wdyspnea_control = 1 if (o2_post_control - 
o2_pre_control)>0 
label var wdyspnea_control "Worsened Dyspnea" 
 
capture drop ncdyspnea_control 
gen ncdyspnea_control = 0 
replace ncdyspnea_control = 1 if (o2_post_control - 
o2_pre_control)==0 
label var ncdyspnea_control "No Change" 
 
capture drop idyspnea_control 
gen idyspnea_control = 0 
replace idyspnea_control = 1 if (o2_post_control - 
o2_pre_control)<0 
label var idyspnea_control "Improved Dyspnea" 
 
*  Generate Mean LOS after Intervention (or Equiv) for 
Cases and Controls 
 
capture drop mlos_case 
gen mlos_case = los_case - pod_int_case 
label var mlos_case "Post Intervention Length of Stay 
(Case)" 
 
capture drop mlos_control 
gen mlos_control = los_control - pod_int_control 
label var mlos_control "Equivalent Length of Stay (Control)" 
 
* Generate and Label POD_INT + 1d (or Equivalent) 
Variables for Cases and Controls 
 
capture drop pod_equiv_o2_case 
gen pod_equiv_o2_case = 0 
 
capture drop pod_equiv_af_case 
gen pod_equiv_af_case = 0 
 
capture drop pod_equiv_amio_case 
gen pod_equiv_amio_case = 0 
 
capture drop pod_equiv_fev_case 
gen pod_equiv_fev_case = 0 
 
capture drop pod_equiv_wbc_case 
gen pod_equiv_wbc_case = 0 
 
capture drop pod_equiv_plts_case 
gen pod_equiv_plts_case = 0 
 
replace pod_equiv_o2_case = pod4_o2_case if pod_int_case 
== 3 
replace pod_equiv_af_case = pod4_af_case if pod_int_case 
== 3 
replace pod_equiv_amio_case = pod4_amio_case if 
pod_int_case == 3 
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replace pod_equiv_fev_case = pod4_fev_case if 
pod_int_case == 3 
replace pod_equiv_wbc_case = pod4_wbc_case if 
pod_int_case == 3 
replace pod_equiv_plts_case = pod4_plts_case if 
pod_int_case == 3 
 
replace pod_equiv_o2_case = pod5_o2_case if pod_int_case 
== 4 
replace pod_equiv_af_case = pod5_af_case if pod_int_case 
== 4 
replace pod_equiv_amio_case = pod5_amio_case if 
pod_int_case == 4 
replace pod_equiv_fev_case = pod5_fev_case if 
pod_int_case == 4 
replace pod_equiv_wbc_case = pod5_wbc_case if 
pod_int_case == 4 
replace pod_equiv_plts_case = pod5_plts_case if 
pod_int_case == 4 
 
replace pod_equiv_o2_case = pod6_o2_case if pod_int_case 
== 5 
replace pod_equiv_af_case = pod6_af_case if pod_int_case 
== 5 
replace pod_equiv_amio_case = pod6_amio_case if 
pod_int_case == 5 
replace pod_equiv_fev_case = pod6_fev_case if 
pod_int_case == 5 
replace pod_equiv_wbc_case = pod6_wbc_case if 
pod_int_case == 5 
replace pod_equiv_plts_case = pod6_plts_case if 
pod_int_case == 5 
 
replace pod_equiv_o2_case = pod7_o2_case if pod_int_case 
== 6 
replace pod_equiv_af_case = pod7_af_case if pod_int_case 
== 6 
replace pod_equiv_amio_case = pod7_amio_case if 
pod_int_case == 6 
replace pod_equiv_fev_case = pod7_fev_case if 
pod_int_case == 6 
replace pod_equiv_wbc_case = pod7_wbc_case if 
pod_int_case == 6 
replace pod_equiv_plts_case = pod7_plts_case if 
pod_int_case == 6 
 
capture drop pod_equiv_o2_control 
gen pod_equiv_o2_control = 0 
 
capture drop pod_equiv_af_control 
gen pod_equiv_af_control = 0 
 
capture drop pod_equiv_amio_control 
gen pod_equiv_amio_control = 0 
 
capture drop pod_equiv_fev_control 
gen pod_equiv_fev_control = 0 
 
capture drop pod_equiv_wbc_control 
gen pod_equiv_wbc_control = 0 
 
capture drop pod_equiv_plts_control 
gen pod_equiv_plts_control = 0 
 
replace pod_equiv_o2_control = pod4_o2_control if 
pod_int_control == 3 
replace pod_equiv_af_control = pod4_af_control if 
pod_int_control == 3 
replace pod_equiv_amio_control = pod4_amio_control if 
pod_int_control == 3 
replace pod_equiv_fev_control = pod4_fev_control if 
pod_int_control == 3 
replace pod_equiv_wbc_control = pod4_wbc_control if 
pod_int_control == 3 
replace pod_equiv_plts_control = pod4_plts_control if 
pod_int_control == 3 
 
replace pod_equiv_o2_control = pod5_o2_control if 
pod_int_control == 4 
replace pod_equiv_af_control = pod5_af_control if 
pod_int_control == 4 
replace pod_equiv_amio_control = pod5_amio_control if 
pod_int_control == 4 
replace pod_equiv_fev_control = pod5_fev_control if 
pod_int_control == 4 
replace pod_equiv_wbc_control = pod5_wbc_control if 
pod_int_control == 4 
replace pod_equiv_plts_control = pod5_plts_control if 
pod_int_control == 4 
 
replace pod_equiv_o2_control = pod6_o2_control if 
pod_int_control == 5 
replace pod_equiv_af_control = pod6_af_control if 
pod_int_control == 5 
replace pod_equiv_amio_control = pod6_amio_control if 
pod_int_control == 5 
replace pod_equiv_fev_control = pod6_fev_control if 
pod_int_control == 5 
replace pod_equiv_wbc_control = pod6_wbc_control if 
pod_int_control == 5 
replace pod_equiv_plts_control = pod6_plts_control if 
pod_int_control == 5 
 
replace pod_equiv_o2_control = pod7_o2_control if 
pod_int_control == 6 
replace pod_equiv_af_control = pod7_af_control if 
pod_int_control == 6 
replace pod_equiv_amio_control = pod7_amio_control if 
pod_int_control == 6 
replace pod_equiv_fev_control = pod7_fev_control if 
pod_int_control == 6 
replace pod_equiv_wbc_control = pod7_wbc_control if 
pod_int_control == 6 
replace pod_equiv_plts_control = pod7_plts_control if 
pod_int_control == 6 
 
label var pod_equiv_o2_case "Case - Peak O2 Req." 
label var pod_equiv_o2_control "Control - Peak Equiv O2 
Req." 
 
label values pod_equiv_o2_case o2_lbl 
label values pod_equiv_o2_control o2_lbl 
 
label values pod_equiv_af_case yn_lbl 
label values pod_equiv_af_control yn_lbl 
 
label values pod_equiv_fev_case yn_lbl 
label values pod_equiv_fev_control yn_lbl 
 
*  Generate and Label Days of AF for Cases and Controls 
 
capture drop daf_case 
gen daf_case = pod3_af_case + pod4_af_case + 
pod5_af_case + pod6_af_case + pod7_af_case 
label var daf_case "Case Days in AF" 
 
capture drop daf_control 
gen daf_control = pod3_af_control + pod4_af_control + 
pod5_af_control + pod6_af_control + pod7_af_control 
label var daf_control "Control Days in AF" 
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*  Generate and Label Pre- and Post-Intervention Days of AF 
for Cases and Controls 
 
capture drop daf_post_case 
gen daf_post_case = 0 
replace daf_post_case = pod4_af_case + pod5_af_case + 
pod6_af_case + pod7_af_case if pod_int_case==3 
replace daf_post_case = pod5_af_case + pod6_af_case + 
pod7_af_case if pod_int_case==4 
replace daf_post_case = pod6_af_case + pod7_af_case if 
pod_int_case==5 
replace daf_post_case = pod7_af_case if pod_int_case==6 
 
capture drop daf_post_control 
gen daf_post_control = 0 
replace daf_post_control = pod4_af_control + 
pod5_af_control + pod6_af_control + pod7_af_control if 
pod_int_control==3 
replace daf_post_control = pod5_af_control + 
pod6_af_control + pod7_af_control if pod_int_control==4 
replace daf_post_control = pod6_af_control + 
pod7_af_control if pod_int_control==5 
replace daf_post_control = pod7_af_control + dis_af_control 
if pod_int_control==6 
 
capture drop daf_pre_case 
gen daf_pre_case = 0 
replace daf_pre_case = daf_case - daf_post_case + 
pod3_af_case if pod_int_case==3 
replace daf_pre_case = daf_case - daf_post_case + 
pod4_af_case if pod_int_case==4 
replace daf_pre_case = daf_case - daf_post_case + 
pod5_af_case if pod_int_case==5 
replace daf_pre_case = daf_case - daf_post_case + 
pod6_af_case if pod_int_case==6 
replace daf_pre_case = daf_case - daf_post_case + 
pod7_af_case if pod_int_case==7 
 
capture drop daf_pre_control 
gen daf_pre_control = 0 
replace daf_pre_control = daf_control - daf_post_control + 
pod3_af_control if pod_int_control==3 
replace daf_pre_control = daf_control - daf_post_control + 
pod4_af_control if pod_int_control==4 
replace daf_pre_control = daf_control - daf_post_control + 
pod5_af_control if pod_int_control==5 
replace daf_pre_control = daf_control - daf_post_control + 
pod6_af_control if pod_int_control==6 
replace daf_pre_control = daf_control - daf_post_control + 
pod7_af_control if pod_int_control==7 
 
label var daf_post_case "Case Days AF post-Intervention" 
label var daf_pre_case "Case Days AF pre-Intervention" 
label var daf_post_control "Control Days AF post-
Intervention" 
label var daf_pre_control "Control Days AF pre-
Intervention" 
 
* Generate and Label Post-Intervention Cumulative Doses of 
Amiodarone 
capture drop amio_post_case 
gen amio_post_case = 0 
replace amio_post_case = pod4_amio_case + 
pod5_amio_case + pod6_amio_case + pod7_amio_case if 
pod_int_case==3 
replace amio_post_case = pod5_amio_case + 
pod6_amio_case + pod7_amio_case if pod_int_case==4 
replace amio_post_case = pod6_amio_case + 
pod7_amio_case if pod_int_case==5 
replace amio_post_case = pod7_amio_case if 
pod_int_case==6 
 
capture drop amio_post_control 
gen amio_post_control = 0 
replace amio_post_control = pod4_amio_control + 
pod5_amio_control + pod6_amio_control + 
pod7_amio_control if pod_int_control==3 
replace amio_post_control = pod5_amio_control + 
pod6_amio_control + pod7_amio_control if 
pod_int_control==4 
replace amio_post_control = pod6_amio_control + 
pod7_amio_control if pod_int_control==5 
replace amio_post_control = pod7_amio_control + 
dis_amio_control if pod_int_control==6 
 
label var amio_post_case "Case Total Post-Intervention 
Amiodarone" 
label var amio_post_control "Control Total Post-Intervention 
Amiodarone" 
 
*  Data Generation and Labeling Complete; Ready for 
Endpoints 
 
window stopbox rusure "Variable Generation and Labeling 
Complete.  Display Endpoints?" 
 
****************************** 







window stopbox rusure "Demogrpahic and Baseline Results 
Generated.  Click Yes to Continue or No to Review" 
 
********************** 
** Primary Endpoint ** 
********************** 
 




* Binomial Expansion Test for Improvement >50% 
bitest idyspnea_case == 0.5 
ci idyspnea_case, binomial 
 
* POD of Intervention 
tab pod_int_case pod_int_control 
 
* Regression for Pleural Fluid Removed 
summarize case_vol_case, detail 
regress case_vol_case los_case 
regress case_vol_case o2_diff_case 
 
* Fisher's Exact Test on Improvement Status 
tabulate o2_status_case o2_status_control, exact 
 
* Difference in O2 Requirement after Thoracentesis for 
Cases and Controls 
 
window stopbox rusure "Primary Endpoint Results 
Generated.  Click Yes to Continue or No to Review" 
 
************************ 
** Secondary Endpoint ** 
************************ 
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* Summary of Data 
summarize los_case los_control 
 




* Paired T-test of Hospital LOS 
ttest los_case==los_control 
 
* Regression Analysis of LOS by POD of Thoracentesis 
regress los_case pod_int_case 
 
* Mean LOS from Intervention to Discharge (Cases Only) 
sum mlos_case 
sum mlos_case if pod_int_case<5 
 
window stopbox rusure "Secondary Endpoint Results 
Generated.  Click Yes to Continue or No to Review" 
 
*********************** 





window stopbox rusure "Tertiary Endpoint Results 
Generated.  Click Yes to Continue or No to Review" 
 
****************************** 




** Atrial Fibrillation ** 
************************* 
* Days in AF 
tab daf_case pod_int_case 
 
summarize daf_case if daf_case>0 
summarize daf_control if daf_control>0 
 
* Days in AF if POD of Thoracentesis <5 
summarize daf_case if daf_case>0 & pod_int_case<5 
summarize daf_control if daf_control>0 & pod_int_case<5 
 
*  Requirement for Amiodarone After Thoracentesis 
 
ttest amio_post_case==amio_post_control 
ttest amio_post_case==amio_post_control if pod_int_case<5 
 
* Markers of SIRS or Acute Phase Reaction 
 
summarize mean_wbc_case, detail 












* Incidence of Post Pericardiotomy Syndrome 
 
ttest ppcs_case==ppcs_control  
 




* Pre- Post- Thoracentesis Oxygen Requirement for Cases 
 
ttest o2_pre_case==o2_post_case if pod_int_case>=4 
 
* Save Data 
save "/Users/davidkull/Desktop/Pericardiotomy - Pleural 
Effusion MGMT/DATA/ppcpe_dataset", replace 




** Automated Key Figures ** 
*************************** 
* Primary Endpoint Graph 3 
 
graph twoway (scatter case_vol_case los_case) (lfit 
case_vol_case los_case) 
graph export "/Users/davidkull/Desktop/Pericardiotomy - 
Pleural Effusion MGMT/DATA/Graphs/dysp3.tif", replace 
 
 
* Secondary Endpoint Graph 
 
graph box los_case los_control, ytitle(Days) ytick(##10) 
ymtick(##2) ylabel(#10) 
graph export "/Users/davidkull/Desktop/Pericardiotomy - 
Pleural Effusion MGMT/DATA/Graphs/los.tif", replace 
 
 
* Primary Endpoint Graph 1 
 
clear 
insheet using "/Users/davidkull/Desktop/Pericardiotomy - 
Pleural Effusion MGMT/DATA/PPCPE2.csv" 
label var case_status "Case or Control" 
label var dysp_status "Dyspnea Change" 
label var mean "Proportion" 
label var n "Number of Patients" 
 
capture label drop case_lbl 
label define case_lbl 1 "Case" 2 "Control" 
label values case_status case_lbl 
 
capture label drop dysp_lbl 
label define dysp_lbl 1 "Improved Dyspnea" 2 "No Change" 
3 "Worsened Dyspnea" 
label values dysp_status dysp_lbl 
 
generate hidysp = mean + (invttail(n-1,0.025)*(sd / sqrt(n))) 
generate lodysp = mean - (invttail(n-1,0.025)*(sd / sqrt(n))) 
replace hidysp = 0.9108 in 1 
replace lodysp = 0.4483 in 1 
replace hidysp = .7258 in 2 
replace lodysp = .2228 in 2 
replace hidysp = .7258 in 4 
replace lodysp = .2228 in 4 
replace hidysp = .4162 in 3 
replace lodysp = .0234 in 3 
replace hidysp = .4162 in 5 
replace lodysp = .0234 in 5 
replace hidysp = .3397 in 6 
replace lodysp = .0035 in 6 
 
generate rank = case_status      if dysp_status == 1 
replace  rank = case_status+2    if dysp_status == 2 
Page 67 of 67 
  
replace  rank = case_status+4    if dysp_status == 3 
sort rank 
list rank dysp_status case_status, sepby(case_status) 
 
graph twoway (bar mean rank if case_status==1) (bar mean 
rank if case_status==2)(rcap hidysp lodysp rank), 
legend(row(1) order(1 "Case" 2 "Control")) xlabel( 1.5 
"Improved Dyspnea" 3.5 "No Change" 5.5 "Worsened 
Dyspnea", noticks) xtitle("Changes in Dyspnea") 
ytitle("Proportion of Patients") 
graph export "/Users/davidkull/Desktop/Pericardiotomy - 
Pleural Effusion MGMT/DATA/Graphs/dysp.tif", replace 
 
save "/Users/davidkull/Desktop/Pericardiotomy - Pleural 
Effusion MGMT/DATA/ppcpe_dataset_graph1", replace 
set more off 
 
* Primary Endpoint Graph 2 
clear 
insheet using "/Users/davidkull/Desktop/Pericardiotomy - 
Pleural Effusion MGMT/DATA/PPCPE3.csv" 
label var case_status "Case or Control" 
label var pre_post "Pre or Post" 
label var mean "Mean" 
label var sd "Standard Deviation" 
label var n "n" 
 
capture label drop case_lbl 
label define case_lbl 1 "Case" 2 "Control" 
label values case_status case_lbl 
 
capture label drop pre_post_lbl 
label define pre_post_lbl 1 "Pre-Intervention or Equiv" 2 
"Post-Intervention or Equiv" 
label values pre_post pre_post_lbl 
 
generate hici = mean + (invttail(n-1,0.025)*(sd / sqrt(n))) 
generate loci = mean - (invttail(n-1,0.025)*(sd / sqrt(n))) 
 
graph twoway (bar mean rank if pre_post==1) (bar mean 
rank if pre_post==2)(rcap hici loci rank), legend(row(1) 
order(1 "Pre-Intervention or Equiv" 2 "Post-Intervention or 
Equiv")) xlabel( 1.5 "Cases" 3.5 "Controls", noticks) 
xtitle("Grouping") ytitle("Daily Peak O2 Requirement") 
graph export "/Users/davidkull/Desktop/Pericardiotomy - 
Pleural Effusion MGMT/DATA/Graphs/dysp2.tif", replace 
 
 
* Close log 
log close 
 
* Save Data 
save "/Users/davidkull/Desktop/Pericardiotomy - Pleural 
Effusion MGMT/DATA/ppcpe_dataset_graph", replace 
set more off 
 
 
